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CHAPTER 1 
INTRODUCTION 
The importance of drug-serum protein interaction was vividly demon-
strated by Sellers and Koch-Weser in 1970! They showed an enhancement of 
the bY,pOprothrombinemic action of warfarin :following simu1taneous daily 
administration of warfa.t'in and chloral. hydrate over a period of seven con-
secutive days. Sellers and Koch-Weser indicated that the mechanism in-
volved was the displacement of warfarin from serum-albumin binding sites by 
trichloracetic acid, a metabolite of chloral. hydrate. The authors provided 
in vivo evidence as well as in vitro warfarin-human serum albumin binding 
data to support their conclusions. Prior to this study, chloral hydrate 
was thought to alter the hypoprothrombinemic effect of warfarin by induc-
tion of the hepatic enzymes required for the metabolic inactivation of 
warfarin. The Sellers and Koch-Weser study represents an important contri-
bution to the field of drug-serum protein interaction as ·it demonstrates a 
direct relationship between the clinical. effectiveness of a drug and its 
binding to serum proteins. 
There are two excellent articles which survey the years of research 
associated with drug-serum protein interactions. An in depth review by 
Goldstein (1949) concerning drug and plasma protein interactions focused 
upon the consequences of the drug-protein complex on efficacy, half-life, 
distribution, and excretion of drugs. Goldstein indicated that much of the 
' drug-protein interaction work in application to the~.!!!£. situation had 
been "conceptual and inconclusive, leading to confusion rather than clarity". 
This indictment was inte~ded to fall. upon the mass of literature published 
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prior to J.942. Although the effect of drug-protein binding in the ·Cl.inical. 
situation is stil.J. a complex question, the conf'usion as to drug inactiva-
. . 
tion by its interaction with serum proteins has been answered and "Positive 
steps have been taken to Cl.arify the relationship between drug-protein inter-
action and Cl.inical. drug activity. Golds~ein's statement that "the cape.-
city of drug molecules to enter into specific combinations with proteins 
poses for pharmacology its most fundamental task - to comprehend the inti-
mate nature of drug action in terms of these molecular interactions" empha-
sizes the importance of drug-protein interaction. 
The Goldstein review contributed to an increased awareness of, and 
stimulated many investigators to study, the phenomenon of the drug-protein 
complex. The resurgence of interest was greatly aided by Cohn et al. (1946) 
who, through alcohol fractionation and eJ.ectrophoretic analysis, developed 
a system for separating protein and lipoprotein fractions of biological. 
tissues and fluids. Since 1949, considerable effort has been spent in de-
scribing and Cl.arifying the binding of a considerable portion of the new 
drugs now available. 
In 1968, Meyer and Guttman reviewed drug-protein binding research for 
the period between 1949 and 1968. In very brief tabular form, they sum-
~ 
marized the interaction between serum proteins and hypnotics, anticoagulants, j 
CNS stimulatns, anti-infectives, cardiovascular agents, psychotropics, etc. I 
Their review indicated that ,!!! vitro and in ~ evidence amply. demonstrated l 
I that the serum protein bindi~ can influence the distributional, pharma-
! 
cological, and pha.rmacokinetic properties of certain drugs. The drug-protein l 
interaction phenomena is now being more caref'uJJ.y scrutinized in terms of , 
. ! 
I 
' ' 
I 
' possible clinical ir.iplicq.tions. Meyer o.nd Guttman caution that "evidence 
i I I ~"'·"'----------·-·-.. ..---·-...r-~.:-......,.,--v~-~.~----------,,._,..,._,.,._,._...._.,.,,., . ..,,___ t 
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exists that onJ.y in the case of highly bound a.gents wil1 binding be impor-
tant in a. practical. sense". They conc1ude: "A number of important drugs 
do, however, fall in the category of 1 strongly bound' and they serve a.s 
examples which emphasize the need to a.t lea.st consider protein binding as a. 
necessary parameter in the characterization of drug behavior". 
The phenomena. known a.s drug-serum protein binding has been a. subject of 
research and speculation f'or seventy-three yea.rs. The primary impetus for 
stimulating _this interest may be attributed to four investigators. In 1898, 
Mathews reported some of the first laboratory observations involving the 
interaction of proteins with chemical. agents •. Mathews indicated that food 
stuffs combined chemically with coagulated egg albumin in solution. 
Heid~nhain (1902) added fUrther evidence when he reported that aniline dyes 
combined chemically with egg albumin. At approximately the same time, Moore 
and Roaf became involved with the drug-serum interactions. These two inves-
tigators demonstrated in 1904 that chloroform and ether had a greater solu-
bility in serum than in saline. They attributed the increased drug solu-
bility to "substance interaction with proteins". Since 1904, the literature 
is replete with references to various aspects of. drug-protein interaction. j 
The implications inherent in the initial. findings of Mathews, Heindenhain,. 
Moore and Roaf did not become readily apparent until the 1920' s. Between 
1920 and 1942, a host of' investigators began to delve into the questions 
posed by the interaction of drugs with serum and serum proteins. Due to 
limited instrumentation and technology, research was limited to dyes, plant 
; extracts and the few ptire drugs readily available. Nevertheless, answers as 
; to which proteins were combining with drugs, what occurs after the union, 
and what effect does a change in hydrogen ion concentration have upon the 
drug-protein complex, were being provided. 
In 1913 Oppenheimer determined that the addition of serum to digitoxin 
solutions marked1y diminished the digitoxin toxicity to the isolated frog 
heart. The time lag, apparently due to technology, was evident since it was 
not until 1931 that Hoekstra, and BrUke ill 1934, confirmed and extended 
Oppenheimer's work, finding that rabbit serum could completely protect the 
isolated frog heart from digitoxin poisoning. It was not until 1944 that it 
was determined what constituent of serum was responsible for the digitoxin 
inactivation. Fawaz and Farah found that the protection against digitoxin 
(1:100,000) poisoning in the isolated frog heart appeared to be due to the 
albumin fraction. Furthermore, this protective action was directly propor-
tiona.l to the protein content of the.solution. Two percent rabbit serulll 
globulin, lipids, and soluble proteins extracted from the heart, liver and 
striated muscle, were not found to decrease digitoxin toxicity. 
pared to those observed with piloca.rpine aJ.one dissolved in saJ.ine. The in- j 
activation of the drug was attributed to a physicaJ. combination or adsorption 1 
I 
to the "Colloids" or some substance in serum, rather than a chemicaJ. change. 1 
He stated that a chemicaJ. change would cause drug destruction which had not I 
occurred. To determine the ~ssible in vivo significance of this drug-serum l 
interaction, cats were treated with pilocarpine solubilized in serum. 
a.nimaJ.s, injected i.v. with 10 mg./Kg. non-serum pilocarpine solutions, 
The . I 
l 
I 
exhibited salivation, ~pnea, vomiting and sometimes death, while cats treat4 
L .. ,. ... -.--.. -----,.,~.~ ,___,_,_,..,._,,....,...._..., ... ~""-......._......_~-"---"-"--'· ..... ,,,..., .. ,,,.__,,,,.~ 
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ed with serum solutions containing the same amount of pilocarpine had less 
intense symptoms with only slight dyspnea. No deaths occurred. 
Continuing with his work, Storm Van Leeuwen teamed with Zeigrier (1921) to · 
repeat the prior work but included atropine. They stated: "Very often we 
found that a solution of 1 mg. of atropine in 5 cc. of rabbit serum showed 
only one-thirtieth or one-fortieth the original strength, so that a.bout 96 
or 98 percent of the atropine had been brought into an inactive form." How-
ever, they also found that cat serum, human serum, milk, etc. had little or 
no adsorbing power for atropine. Since at that time the presence of atro-
pinesterase in certain rabbit strains was not known, they concluded that the 
difference in adsorbing power could be ascribed to differences in "colloidal 
nature" of the various serums. It took another thirty-six years before the 
interaction of atropine with the plasma proteins of other species was docu-
mented. Tonnesen (1956) reported that 50% of a therapeutic dose of atropine 
was absorbed onto the plasma. proteins in man. He postulated that the slow 
elimination of the drug in man might be due to its interaction with plasma. 
protein. Tonnesen surmised that the plasma. proteins served a.s a. carrier by 
! which atropine was transported to various organs, and intimated that the 
drug protein binding may slow the elimination of atropine in man. 
In 1920, Dale reported that histamine was about ten times more toxic for ! 
( cats anesthetized with ether or chloroform than for the unanesthetized animal •. : 
This work spurred Storm Van Leeuwen and von Szent-Gyorgyi {1921) to investi-
gate the influ~nce of anesthe~ics and other drugs upon the piloca.rpine-serum- '. 
protein relationship. Using the isolated gut preparation, they determined 
that piloca.rpine mixed with serum from anesthetized rabbits had less binding 
power than normal serum.• This was shown by the greater ability of the latter ; 
to cause a lllUch stronger gut contraction. Ether decreased the pilocarpine 
binding power of serum more than chloroform. Peptone had a aim11 a.r effect 
whereas urethane, magnesium sul.fa.te, starch and lecithin ha.d no influence. 
The theory concerning pilocarpine inactivation wa.s modified to renect this 
new evidence. They concluded that serum contained substances which inhibit 
atropine and pilocarpine by some physio-chemica.l process, presumably adsorp-
tion. 
In 1924~ Storm Van Leeuwen wrote a. series of short articles renecting 
upon the possible relationship between drug antagonism, drug sensitivity, 
and the drug-protein complex. He theorized that the reaction between a. drug 
and the dominant receptor a.t the site of action was not a. simple one, and 
that it was greatly innuenced by the chemical and physical composition of 
the blood and other tissues. He stated that when two drugs are introduced 
into the body concomitantly, "it is likely that one drug will be more easily 
adsorbed than the other one". This, he continued, was. especially true if 
both drugs had the same dominant receptors. The concomitant administration 
of drugs having similar effects might be antagonistic due to receptor compe-
tition. In this case, one drug acting alone might be more effective than if 
used in comb ina.tion. 
Storm Van Leeuwen (1924) also offered the drug-protein interaction phe-
nomena a.s a possible explanation for certain cases of drug hypersensitivity 
in man. He indicated that drug hypersensitivity appears to be both qua.lita.-
tive and quantitative in nature. "Although the chemical constitution and 
the 'normal' pharmacological actions of a. drug, which may ca.use allergic 
sympto~s, vary very considerably, the sy:~ptoms of h;ypersensitiveness are a.s 
these drugs induce in normal men." He asserted tha.t in "quantitative hyper• 
sensitivity", patients react the same as normals except at 1-ower dc>ses. 
Drug toxicity in normal individuals sirnpJ.y requires higher doses. In "qual-
itative hypersensitivity", he placed those patients who respond se1ectiveJ.y 
to different drugs, i.e. some respond to aspirin, others to boric acid. 
storm Van Leeuwen presented the fol.l.owing example of the effect of protein 
binding power on patients hypersensitive to saJ.icylates. In normal patients, 
0.76 - 0.90 mg. of salicylate/5 cc was found bound to serum. In hypersen-
sitive asthmatics, o.45 - 0.56 of the saJ.icylate was bound. In an attempt 
to desensitize, patients were treated with various proteins, and saJ.icylate 
-
binding to serum achieved levels of 0.78 m.g./5 cc. In his conclusions, 
Storm Van Leeuwen hypothesized that qualitative hypersensitivity may be ~sso­
ciated with the inhibitor action of normal sera and that possible augmenting 
influences may occur due to the presence of other drugs. 
Thus, between the years 1921 and 1924, Storm Van Leeuwen asked questions 
and postulated answers to problems concerning the influence of protein bind- I 
ing upon the pharmacological activity of drugs. Although some of his theories 
have borne fruit, such as the interference with the drug-protein complex by ! 
the presence of other drugs, the relationship between patient variation in 
drug dosage effectiveness and drug-protein interaction is stil.l. unresolved. 
From 1923 until 1942, research in this field appeared to be concerned 
primarily with the novelty of drug-protein binding. Which drugs a.re bound? 
how do they form a protein at.lachment? and what is the strength of this asso- · 
ciation? Oliver and Douglas (1922-1923) investigated protein binding of 
arsphenamine. These researchers found that gum arabic, es;g albumin, plasma 
proteins, and specificaJ::ly the globulins, form complexes with arsphenamine 
-7-
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and inorganic a.rsenates both in vitro and in vivo. The arspbenamine content 
of the drug-protein complex was found to vary with the hydrogen ion concen-
tration. They observed that the degree of binding was increased as the pH 
of the medium increased. They also determined that protection afforded by 
hydrophilic colloids against the agglutination of red blood cells by ars- . 
phenamine was due to the union of the former with the latter, which prevented I 
the binding of the arsphenamine by the cells. The change in the coa.gul.ating 
properties Qf the plasma proteins after the injection of a.rsphenamine was • 
explained by the assumption that the compound with a.rsphenamine was soluble 
at certain high concentrations. 
Until 1925, investigation of the drug-protein complex was of a semi-
quantitative nature. In 1925, it appears· that Grollman mey- have published 
the first really quantitative work, studying the combination of phenolsulo-
nephthalein (phenol red} with blood serum and albumin of various animal 
species. Using an ultrafiltration method, he determined that as the percent-
age of albumin was increased, the percent of uncombined dye decreased. 
Grollman reported that the binding of the dye followed the equation 
X/m = Kc l/n, in which X = millimoles of dye absorbed by m, gram of adsor-
bent, and c is the concentration of dye in millimoles per liter. K and n 
are constants with n being equal to l for proteins. Grollman also found 
species difference in drug-protein binding. He reported that phenol red was 
bound by the blood proteins of the rabbit 95%, dog 75%, pig 75%, hen 54%, 
duck 53%, and frog 20%. ' 
Beutner (1925), while discussing drug-protein interaction, recognized 
that "the binding power of the serum is an important physiological phenom-
enon and certainly plays•a role in all pharmacological actions". He cites 
~,_,, __ 
~ 
' 
Jendrassiks' procedure (1922) :for equilibrium dialysis as a tool to test the 
serum binding power o:f drugs. In 1926, :Beutner determined that rabbit serum 
bound more pilocarpine than the serum o:f cattle. However, he reported "the 
binding is looser", or more easily reversed, :for rabbit serum. 
Rosenthal (1925) studied the dissociation o:r drugs bound to protein. He 
reported that the union between dog serum proteins a.nd tetrachlortetraiodo-
fluorecein {rose bengal) or bromosulphalein were completely bound in vitro to 
proteins o:f the blood. He found that the presence of bile salts caused a 
liberation of the dye stu:ff' which was not due to PI'.Otein precipitation. 
Phenolsulphonephthalein, which was partially bound by blood proteins, was 
also dissociated by bile salts. Subsequently, Rosenthal (1926) reported 
that undiluted dog serum bound 65% of the phenol red in the solution, while 
a. 0.1% serum solution bound the same quantity of rose ban.gal. He determined 
that molecular aggregation occurred in very dilute aqueous solutions. Using 
strongly acid (pH 2) solutions of serum albumin, gelatin, globulin, and dog 
serum, he found that the amount of dye bound to the colloid followed the 
classical Freundlich absorption isotherm equation 
log ~ = k + : log P 
m ?t I 
· where x is the mass I absorbed, m is the absorbent mass, k end n are experi-
~ mentally determined constants, and P is the pressure. Finally, the author 
found that the addition of 25 mg, of Na Oleate/cc. of whole dog blood in-
creased the non-protein filtrates 20-55%. Rosenthal attributed this in-
' crease to the liberation of non-protein nitrogenous substances which ordin-
arily remain attached to the proteins and do not appear in the filtrates. 
Thus, during the yer:rs 1925 and 1926, recognition of drug-protein affin-
I 
i 
I 
I 
ity, drUg interference or receptor site competition, a.nd species differences 
in the drug-protein complex became apparent. Undoubtedly, the efforts of 
Grollman, Beutner, Rosenthal and others has led to the present day specula-
tion and emphasis on the importance of drug-protein association constants. 
By 1926, the era of qualitative drug-protein binding research has begun a.nd 
the importance of the strength of the drug-protein bond (affinity) has been 
recognized. 
The attraction of plasma proteins for sterols was studied by Gardner a.nd 
Gainsborough (1927). These workers found a close association between choles-
terol and serum proteins, the most dramatic combinations being with euglob-
ulin. They indicated that it was not :possible to conclude that the cholest-
erol-protein complex was chemical in the ordinary sense, but that there was 
really no sharp distinction between so-called physical ahsorption and chem-
ical union of associated substances. Gardner and Gainsborough reported that 
changes in the globulin albumin ratio in plasma most likely have some influ-
ence on the variations in sterol content of the plasma under normaJ. physio-
logical conditions and in disease. 
In 1927, Hewitt investigated complex between proteins and phthalein-
fluorecein dyes, such as rose bengal, bromophenol blue, eosin, fluorescein, 
erythrosin, phenolsulphone:phthalein, and :phloxin. He reported that the 
colors which change on the acid side of the isoelectric point of the proteins 
were not discharged or altered with acidification after being mixed with egg 
or serum albumin. This non-rttsponsiveness to pH changes was attributed to a 
dye-protein combination :phenomena. Hewitt states that this dye-protein asso- . 
ciation was not "surface absorption" but a chemical combination • 
. -10-
serum proteins were binding drugs and the extent of the a.i'f'inity.. He report-
ed that coagulated solutions of egg albumin had a greater af'finity·for anti-
septic dyes than serum protein solutions. He reinforced Rosenthal.'s findings 
by determining that the interaction between solutions of purified egg albumin' 
and triphenyl.methane dyes, crystal violet, malachite green, and bril.lie.nt 
green obeyed the Freundlich absorption isotherm equation. Finall.y, Hersh-
felder found that the affinity of the dyes for the protein was increased by 
the· introduction of aJ.kyl groups into the dye molecule. 
. . 
Within seven years, investigators were studying the relationship between 
drugs and individual serum protein entities. Gutman and Gutman {1937) 
studied clinically the relationship of serum calcium to total serum protein 
and serum protein fractions. They discovered a direct proportionality be-
tween protein and total calcium in sera from normal and nephrotic patients. 
However, calcium levels were not found to rise above normal in hyperprotein-
emia. They concluded that serum calcium was composed of (1) calcium bound to I 
. I 
and proportional to the albumin concentration; (2) calcium bound to a globu- I 
lin fraction which remains relatively constant in a.mount regardless of the I 
total globulin level; (3) a small fraction of caJ.cium bound to another globu- ! 
f 
lin fraction which increases with the total globulin level but becomes signi- ; 
fica.nt only in marked hyperglobinemia; (4) caJ.cium not bound to protein. 
immunologists became increasingly interested in the relationship between 
the drug-protein complex and antigen formation. In 1937, Mulinos and Schles-: 
' -
inger cite the 1917 research ~f Landstiner and Lampl as a stimulus for their 
antigen work. Landsteiner and Lampl showed that new protein antigens could 
be formed through the chemical union betlreen chemicaJ.ly simple drugs such as 
aniline and a protein. Xhis finding led Mulinos and Schlesinger to diazotize 
-11-
a.ntipyrine and couple it to. rabbit serum a.nd egg white aJ.bumin. Using the 
isolated guinea pig uterus preparation, they demonstrated that by this mea.ns 
antipyrine could be coupled to proteins to form new antigens. 
Du.ring the years 194o-1943, the true pharmacological implications of 
drug-protein binding as envisioned by Storm Va.n Leeuwen and Beutner began to 
unfold. Butler and associates (1940) reported on their studies in synthetic 
iJDmUnochemistry. They indicated that an aspirin-serum globulin (horse and 
rabbit) co~lex produced a powerful antigen. These investigators then ob-
tained an aspirin-protein complex antisera by injecting pyretic rabbits with 
i 
this antigen. After treating normaJ. rabbits with the antisera, they observed l 
that the antipyretic effect of aspirin was diminished. Butler et aJ. state 
that this "demonstrates the possibility of neutraJ.izing the effect of a 
pharmacologicaJ.ly active group with a.n antiserum against a protein in which 
this group is acting as a haptene, even though the group in question has no 
chemicaJ. connection with protein itself." The attachment of the haptene to 
the antibody appeared to be preventing the former from reaching its normal 
site of action in the body and therefore from exercising its usual physio-
logicaJ. effects. 
In 1941, Bassett, SaJ.ter and co-workers did an extensive study of the 
blood protein-iodine complex. These investigators determined that the aJ.bu-
min fraction of both horse and human serum was the major iodine binding pro-
tein. Their results suggested that blood plasma-protein bound-iodine might 
serve as a useful index for circulating thyroid hormone. Later in the year 
' 
this group demonstrated clinically that plasma-bound iodine appeared to be a i 
highly reliable and sensitive criterion for diagnosing hypothyroidism. 
While working with sulfonamides, Davis made a major contribution involv-
-12-
effect of the drug-protein complex in re1ationship to pharma~ 
cologica1 activity. During the years 1942-1943, Davis reported that su1fon-
amide, su1fapyridine, su1fadiazine serum protein binding was due to albumin. 
I 
He indicated that the degree o:f binding accounted for the distribution of the I 
drllgs in the boey fiuids and their increased solubility in p1asma. He found I 
that over a pH range of 6.o - 8.5, su1fa drug binding increased with increas~ I 
:t.ng alkalinity, suggesting that anionic dissociation of the su1fonamides was 
a factor in binding. More significantly, Davis tested the bacteriostatic 
activity of these su1fonamides in the presence of a1bumin. Davis was able to l 
conc1ude that protein-bound su1fonamides appeared to be bacteriostatica11y 
inactive. Finally, Davis and Wood (1942) found a quantitative correlation 
between su1fonamide -protein binding.tendency and bacteriostatic activity. 
Protein binding work, like most basic investigation, was curtailed be-
tween 1941 and 1946 due to war. After World War II, advanced technology 
enabled investigators with drug-protein complex interests to become more 
active. The application of new methodology and instrumentation a11owed both 
i qualitative and quantitative measurement of drug-protein binding sites, esti- i 
mation of drug-protein affinity through the use of association constants, and! 
drug inactivation after protein binding. I 
l. Contra.sting resu1ts were reported concerning the effects of serum, blood, 1 
living tissues or their autolytic products on the bacteriocidal activity of 
I 
I 
l 
penicillin. Chow and McKee (1945) reported that penicillin combined with I 
htunan serum a1bumin but did n•t appear to complex with the g1obu1ins. They / 
stated that, unlike the albumin-sulfonamide complexes, the penicillin-a1bumin, 
l 
' complex possessed antibiotic activity. Thus, doubt was cast upon the theory 
' that pharmacological inaetivntion occurred after the formation of a drug-
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I 
serum protein comp1ex. However, in a thorough stuccy, Ea.gl.e (1947) demonstra-
ted that penicil1ins F, G, K, and X were all. rendered bio1ogica.J.ly inactive 
by human a.nd rabbit serum. The author stressed tha.t in vivo ineffectiveness 
of penicillin may be due not on1y to rapid excretion of the drug but also to 
the fa.ct that as b1ood-drug concentra.tion-fall.s, serum inactivation of peni-
cil1in increases via. a.n increase in binding. 
The definition, determination, and app1ication of binding site c1a.ss iden-
tification and association constants, a.s an expression of drug-protein affin-
ity in the modern context, began in 1946. Kl.otz and his associ.ates (1946-
1948) attempted to clarify drug-protein interaction qua.ntita.tiveJ.y in terms 
of the statistical. and e1ectrosta.tic factors which ·influence binding. These 
investigators were ab1e to determine.the number of serum bovine albumin bind-
ing sites and their association constants for organic ions (metby1 orange, 
azosulfathiazole and some mono- and di-su1fonated eyes) using equations de-
rived from the 1aw of mass action. Varying the pH of the buf'fer so1utions, 
they determined that the binding of organic ions as well as copper diminished . 
I 
as the medium became more acidic. From the pH data, it was conc1uded that l 
the ammonium group of lysine was strongly i:livo1ved in the binding of organic 
ions while the protein carboxy1 groups were the primary factor in the copper-
albumin comp1ex. Fina.J.ly, Kl.otz emphasized that commonly used buf'fer systems 
such as phthal.ate, veronal., and citrate affect proteins by forming comp1exes 
with the protein. These investigators state: "In view of the frequent use 
of these e1ectrolytes in proteful studies, particu1ar1y in investigations of 
electrophoretic mobilities, it is essential. that their affinity for the pro-
tein ~olecule by recoenized and accounted for in any i..~terpetation of the 
physio-chemical behavior•of these large molecu1es." 
I 
' ! 
' . 
Following the 10.otz lead, George Scat chard (1949) made a significant con-
tribution in the area of binding site and association constant identification. 
Using calcu1ations based on the law of mass action, Scatchard determined that l 
plotting r/c, the ratio of the moles of drug bound per mole protein (r) to 
the concentration of free drug (c) against r, wou1d permit the resolution of 
the binding sites (n) and their intrinsic association constants (K). The 
values of n and nK were determined by extrapolation of the resultant plot to 
the appropriate x-y intercepts. He observed that shou1d the plot resu1t in a 
. 
curved line, there were more than one class of binding sites with a separate 
intrinsic association constant for each class of sites. Although published 
in 1949, the Scatchard plot is presently the major technique for the deter-
mination of binding sites and their association constants. If the plot is 
not a straight line but a curve, the curve is resolved into its linear compo-
nents, each of which are then extended to their appropriate intercepts. Usl 
this tool, Scatchard et al (1950) reported two classes of binding sites - · 
n1 = 10, K1 = 44, and~ = 30, ~ = 1.1 for chloride ion on human serum al.bu- j 
I 
min at pH 4.9 - 5.2. They also found that the resu1ts were well described by I 
the law of mass action. 
During this early post World War II era, Fred Ka.rush also became inter-
ested in protein bi.riding. In 1949, Ka.rush and Seonenberg reported on the 
interaction of a1.kyl sulfates and bovine serum albumin. The authors had 
thought sodium octyl, decyl and dodecyl alkyl su1fate to be bound in a homo-
logous manner until they subj~cted bovine serum binding data to the Scatchard 
plot interpretation. "Deviation of the binding curves from the simple theory 
based on the mass action law have shown to be inexplicable on the basis of 
electrostatic effects. ~ new heterogeneity theory based on a particu1ar 
-]5-
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distribution of the intrinsic binding constants has been proposed and has 
been found to account quantitatively for our results." Continuing his in-
vestigations, Karush (1950) reported on the binding of an anionic azo dye, 
p-{2-hydroxy-5-methylphenyl-azo}-benzoic acid, and competitive interactions 
by d.odecyl sulfate with bovine serum albumin. Karush found that bovine serum 
albumin binding sites for the azo dye were heterogeneous, group 1 binding 
sites had a much greater affinity for both drugs than the group 2 sites, and 
that as the concentration of the sulfate was increased, the amount of dye 
bound was diminished. Karush concluded on the basis of binding. studies that 
his results werved to support the concept that the binding properties of serum 
albumins were associated with the configurational adaptability of a numer of 
regions of the protein. He reasoned that the same sites {group 1) strongly 
bound the two structurally different anions, suggested that the binding sites 
had a high degree of structural a.da.ptability, i.e, they could assume struc-
tures which were complementary to a wide range of configurations. He contin-
ued that it was this property which conferred upon the albumins the distinc- i 
! 
tive ability to form compl.exes with a wide variety of anions. Finally, Karushi 
indicated that the secondary sites were restrictive in adaptability, having. I 
smaller association constants which lead to selectivity in association. 
Weiner ~ al. (1950) investigated the physiological disposition of di-
cumarol clinically. Using .!E. vitro dialysis experiments and bl.ood taken from 
patients, they determined that ninety-nine percent of the compound was bound 
by plasma constituents. When \Clicuma.rol was mixed separately with beta and 
gamma globulins, alpha globulin, and albumin, these plasma. proteins bound the 
drug 20, 50 and 99"/o respectively. The low free plasma level., slow rate of 
metaboli~~, slow rate of•biotra.nsformation, and slow elimination rate of the 
I 
!.: 
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anticoaguJ.a.nt were attributed to its extensive binding by plasma proteins. 
The physiological disposition of procainamide and its interaction with 
plasma proteins was investigated by Mark et al (1951). These workers deter i 
mined that procainamide was principally localized in kidney liver spJ.een - I 
1ung, etc. They found that 15% of the drug was bound to non-diffusible ele- I 
ments of plasma. Ai'ter allowing for a 1-hour drug metabolism-excretion per- I 
iod, the authors found that: "Organ tissues reversibly localize considerable 1 
I 
amounts of the drug which are released to the plasma as the drug is lost by 
metabolic transformation or urinary excretion." 
Scrutiny of the barbiturate-serum protein complex began about 1950 when 
Goldbaum and Smith investigated the binding of various barbiturates by tissue 
homogenates. Their resul.ts showed that the order of tissues binding cap~ity 
was liver kidney plasma brain red cells muscle. Theiopental was bound 
to the greatest degree, followed by seconal, pentobarbital, phenobarbital, 
and barbital. After developing a more sensitive ul.traviolet spectrophoto-
metric assay (Goldbaum, 1952), these authors investigated the binding of 
this series of barbiturates with bovine serum albumin (BSA) a.nd its possible 
relationship with pharmacological activity. In 1954, Goldbaum and Smi~h re-
ported that decreasing the substituted alkyl side chain length from six to 
two carbons diminished the percentage of drug bound. The barbiturates hav-
ing the greatest fraction bound also had the shortest duration of activity. 
They determined that the binding of barbiturates was related to pH, protein 
concentration a.nd drug concentration. Goldbaum and Smith observed partial 
. ' 
displacement of the barbiturates from the drug-protein complex with the 
addition of othet barbit&ates of dissimilar organic anions. Finally, they 
estimated the number of barbiturate binding sites per molecul.e of BSA. The 
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I 
l 
I j 
authors concluded: 1) the extent of binding~ vitro appeared to be· pa.rtial.ly 
related to the distribution of drugs in vivo; 2) the degree of protein bind-
! 
i ing correlated fairly well with the known pharmacological properties of the drUSS· .!!!_vitro work by Brown (1969), using phenobarbital Na. a.t concentra-
tions approximating those reported clinicaJ.ly by Sunshine for sedation, con- I 
firmed the pH and protein concentration relationship to drug binding reported I 
by Goldbaum .and Smith. However, human serum a1bumin (BSA) was employed. I 
Browne found that HSA provided approximately 15 phenobarbital binding sites 
per molecule. of albumin as compared to 21. 7 for BSA reported by Goldbaum. 
Tey-lor ~ .!!:!.· (1954) studied~~ and~ vitro binding of thiopenta.l 
by rabbit plasma. Their results also corroborated the data. of Goldbaum and 
Smith showing that the amount of drug b~d ~vitro closely resembled the 
aznount bound in vivo. It was demonstrated that as the concentration of thio-
pent.al increased, the percentage of drug bound diminished, resulting in a 
prolongation of sleeping time duration. FinaJ.ly, Tey-lor found a. positive 
correlation between bovine and human serum albumin binding and the enhance-
ment of sleeping time. 
Examining the fate of barbital, phenobarbital, and allypropymaJ. in man,_ 
j 
! 
I 
. l 
Lous (1954) determined that the percentage of barbiturate bound to plasma was l 
l 
95% (88-104) for barbital, 50% (33-71) for phenobarbital, and 60% (54-65) for i 
. i 
a.llypropymal. These values also approximat~ the values reported by Goldbaum 
and Smith. Unfortunately, Lous did not determine nor identify the serum 
protein or pH of his sa.':lples. Wadell and Butler (1957) further examined the 
~ 
distribution and excretion of phenobarbital in dog, mice and men. These 
authors found that the percentage of drug bound~ vitro was minimally af-
fected by pH variation. In contrast to in vitro findings, in vivo experiments' 
. - --
' 
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in dogs, mice and man revealed that after causing a.lka.losi~ induced. by intra-
venous infusion of Na.Hco3 or eyperventilation and acidosis from co2 inhala-
tion, plasma phenobarbital. concentrations rose with the elevation of pH. 
AJ.kalosis was found to lighten phenobarbital. anesthesia by diminishing drug 
concentrations in the brain. 
Markus and Karush (1958) investigated the effects of various structures 
of the anionic a.zo dyes on human (HSA) and Bovine (BSA) serum albumin. Em-
ploying equilibrium diaJ.ysis, optical rotation, rotatory dispersion, and 
viscosities, they determined that these eyes affected the opticiµ. rotation 
patterns of HSA and BSA differently. Their results were enterpreted as 
structuraJ. changes in the albumin mo1ecu1e resulting from interaction with 
eye molecules, involving the stabilization of configurations varying in hel-
icaJ. content. The diversity in the rotatory patterns indicated flexibility 
in the aJ.bumin molecules and provided further indirect evidence for the 
Karush concept of configurational. adaptability. 
McMenamy and his associates (1963), while stueying HSA binding and re-
lated thermoeynamic vaJ.ues of 1-tryptopha.n and its anaJ.ogues, added weight 
to' the theory of HSA configurational adaptability. These authors postulated 
that three points of reference were necessary for a compound to· bind to a 
site in a stereospecific manner. These could be either positions of attach-
ment of the 2 interacting molecules or adapted spa.res which permit the mo1-
ecules to come together. Examples given for reference points were the indole 
ring contribution of energy fJ\Dm the indole ring which provided attachment 
by van der Waals forces, an ionizable group on the protein having an associa-
tion constant in the ra.nGe of the tryptophnn imidazole o?' N-terminaJ. groups, 
and spatial. tolerance as•represented by the distance separating the protein 
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N-termina.l. and Cf-amine groups. This spatial. distance must be mna.ll enough 
to be able to provide a mini!D.a.l. repulsive i'orce equivalent to 2 kiloca.l.ories 
when both groups a.re positively charged. The authors al.so determined tha.t 
tryptophan wa.s bound primarily by one site, the binding being pH dependent. 
The association of the indolylethylene group wa.s "attributed to entropy 
changes at the protein site, presumably due to the loss in freedom of the 
bydrophobic groups on the protein". 
The work of Spratt and Okita (1958) provided some information concerning 
the use of radioisotope tracers in drug-protein binding. Earlier, Okita 
(1953) determined the renal. exretion pattern of digitoxin employing randomly 
labeled 14C-digitoxin in a.rterioscierotic heart disease patients with con-
gestive heart failure. Familiarity with radioisotope procedures provided. 
the stimulus and means for Spratt and Okita to investigate the binding of 
digitoxin by ra.t serum proteins and compare their findings with those of 
other investigators. They found that 1 mg. of rat serum protein bound 0,01 
f mcg. of digitoxin when therapeutic doses were employed. These findings were 
f in contrast to those of Rothlin and Ka.l.lenberger (1950) who found tha.t human 
' 
serum albumin bound 2.2 mcg, of digitoxin per milligram of protein. Spratt 
and Okita indicated that in vivo application of the Rothlin and Ka.l.lenberger 
data "is not feasible since it might imply that a normal. man could bind 300 
mg. of the drug without significant pharmacological. effect." 
With the advent of improved liquid scintillation counters, spectrophotom-
etry, new techniques for estin¥tting drug-serum protein binding, i.e. centri-
fugation, Sephadex, etc., exponents of protein binding began investigating 
l the newer dru;;s, hormones, and began re-examining the binding of drugs pre-
. l l Lously inve.tigated, especi~0:~"'~:~~~ inter~~~ in.:_ 
presence of competing ligands. Information concerning multiple drug vis-a-
vis interaction with proteins was not exactly new a,s indicated by studies 
previously discussed; however, new methodology as well as reports of enzyme 
induction and the therapeutic use of drug mixtures caused a renewed interest 
in binding, especially in terms of possible clinical consequences. 
Like Chow and McKee (1946) who indicated that penicillin bound to pro-
tein was pharmacologically active, Paul~~ (1960) published a contradic-
tory note concerning the effect of protein binding upon a drug's activity. 
Paul and his collaborators, working with nitrofurans, determined that plasma 
proteins bound 50-90% of the anionic compounds (nitrofurantoin} while the 
non-ionized drugs (nitrofurazone) were bound approximately 30%. Cationic 
drugs such as furaltadone were not bound to any appreciable extent. However, 
the authors were unable to establish any correlation between plasma binding 
of the drugs examined and their known systemic effects. Unfortunately, nei-
ther the assay method employed nor their detailed results were presented. 
Although the nitrofurans might be the exception, it still remains the author'Q 
opinion that drug-plasma protein complexes are therapeutically inactive. 
Anton (1960,1961) reported that the plasma binding of sulfonamides 
varied markedly between animal species. He quantitatively confirmed that 
albumin binding of sulfaethylthiadiazole (SET), sulfisoxazole, sulfamethoxy-
pyridazine and sulfadiazine inhibited the antibacterial activity of these 
drugs • Anton found that phenylbutazone displaced SET. The author indicated 
a possible practical application for drug displacement; 
' 
by releasing the ac-
tiae drug from its binding, the inactive agent might promote the penetration 
' l 
! 
of the active drug to a particular site. He theorized that not only might it} 
i 
be possible to increase _an a.gent's effectiveness by this procedure, but that ,: 
the availability of a higher concentration of the active drug at the site of 
action might help to decrease the incidence of resistance to chemotherapeutic I 
agents. Anton then presented in vivo evidence showing that the distribution j 
! 
of SET in the rat could be altered by competitive inhibition of its binding ~ 
by plasma proteins through the use of phenylbutazone, ethylbiscoumacetate, I 
sulfinpyrazone and iophenoxic acid. 
I 
"The net effect of displacement in vivo l 
I 
I was a drop in plasma concentration and an increase in the unbound fraction, 
resulting in an increased concentration of sulfonamide (unbound) in tissue." 
1
. 
Finally, Anton and Boyle (1964) reported that the albumin binding of sulfa-
methoxypyridazine interferred with the enzymatic alteration of the drug. 
This effect, they continued, was a· specific one for this particular drug and 
was not observed with sulfani1amide which was insignificantly bound to 
albumin. 
Clausen (1966) established the molecular relationship between a sulfon-
amide and serum proteins. He quantitatively approximated the total number of 
binding sites and the intrinsic association constants per molecule of albumin 
for 3-sulfamido-6-methoxypyridiazine. He also demonstrated that prealbumin, 
glycoproteins, and alpha 2-macroglobulin possessed secondary binding proper-
ties for the drug. He concluded that the binding of sulfonamides may have 
biological importance for the elimination and distribution· of the drug. 
In 1970, Walk.er examined the influence of protein binding on the meta.ho-
lism and excretion of several sulfonamides clinically in man. He determined 
that sulphasomidine, a short-acting sulfonamide, was bound to a lesser extent 
' to plasma albumin than the longer acting agents, i.e. sulphorthodimethoxine. 
Walk.er found that the binding of the sulfonamides investigated "appeared to 
be an important factor i~ determining their excretion rate". Small structur-
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i 
al changes in a drug apparently alters drug-protein binding, i.e, substitu-
tion of a methoxyl group for a methyl group in sulphasomidine in the "4" po-
sition results in a large increase in the percentage of drug bound. 
Earlier, Starn van Leeuwen and Zeijdir (1921), Beutner (1926), and Tonne-
sen (1956) considered the plasma protein binding of atropine in terms of in-
activation, transport, and elimination. In 1962, Oroszlan and Maegwyn-Davies 
published more detailed studies relating to the atropine-albumin complex and 
the effect of acetylcholine upon this interaction. Oroszlan and Maengwyn-
Davies reported that the number of atropine binding sites per molecule of al-
bumin increased from 20 at pH 6 to 100 at pH 8, with only a slight increase 
in association constant at pH 8. They observed that electrostatic and config-
urational changes on the protein would explain the pH dependent binding site 
alterations. The authors demonstrated that the protein binding of atropine 
inhibited the drug's ability to antagonize the effect of acetylcholine (ACh) 
upon the .!!!, vitro rat colon preparation. On the other hand, the addition of 
cysteine interferred with the atropine-protein complex, restoring atropine's I 
l 
demonstrated that ACh fa.cilita.-1. 
attributed "to an alteration in the protein-SH group reactivity". 
The interaction between chemically inert anesthetic gases and albumin was 
I studied by Featherstone et al (1961). These workers found an increase in the 
: solubility of cyclopropane with increasing concentrations of serum albumin. 
i - ' 
~ They state that· Pauling's microcrystal hydrate theory of anesthesia. is consis- ' 
j tent with data presented concerning gas-protein interaction. 
I 
Eich.'llan and his colleagues (1962) worked with xanthines (caffeine, theo-
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pbYlline, theobromine and structura.ll.y reJ.ated compounds). Al.though some of 
the derivatives were bound up to 98%, the bmding of ca.ffeme, theopeyllme 
and theobromine was slight to negligible, and a gradual decrease in bmding 
occurred as the pH was mcreased from 4.8 - 8.5. The authors provided evi-
dence suggesting that m the protem the (-amino group of lysme was respon-
sible for xa.nthine-albumin interaction. 
Between 1964 and 1966, several researchers re-examined the interaction of 
the plasma proteins with various penicillins. Lithander (1964) observed a 
greater percentage of penicillin absorbed by protein when lower concentrations 
of the drug were administered. Al.so the ca.pa.city to complex penicillin was 
reduced as the plasma was diluted. Parallel. investigations by Robinson and 
Sutherland (1965) demonstrated that the binding of penicillin by human serum 
was reversible and independent of antibiotic concentrations beJ.ow 100 mcg./ml. 
Above 100 mcg./ml, penicillin binding diminished with increased drug concen-
tration. They found that temperatures between 4 - 37°C. had little influence. 
Robinson and Sutherland also revealed that phenylbutazone, sodium salicylate 
and sulfonamides interferred with the penicillin-protein complex. Finally, 
they demonstrated direct proportionality between reduction in penicillin anti-
bacterial activity and the extent of its binding by serum. Kunin (1964, 1965~ 
published work involving radio-isotope labelled penicillins and various other I 
antibiotics, as well as known displacing agents was effectively inhibited, 
resulting in an enhancement of microbial activity of the penicillins in the 
I presence of hu.r.ian serum. The S.lfthor indicated that during the equilibration 
I
I period, the rate of drug diffu•ion from the blood into extrava•cular ti•sue• ' 
is controlled by the ar.~unt of free drug. Kunin reiterates that the free drugj 
! may indirectly control the"a.mount of penicillin available for antimicrobial j 
L ' -· _____ ....J 
Thus, binding of the drug and alterations in the drug-protein c.om-
pleX could lead to (l) lower serum levels a.s the relative volume of distribu-
tion increases and, thereby, allows a. greater fraction of the free active drug 
to be available in the extra.vascular, extracellular space; and (2) lower serum 
ievels by increasing renal excretion as the'filtera.ble fraction is expanded. 
Fina.J.ly the author presented evidence showing a. definite relationship between 
serum binding and the side cha.in or R groups 9f the penicillins. He also · 
found that drugs reacting with these R groups were effective inhibitors of 
penicillin-serum binding. 
Reviewing current studies concerning the penicillins, Warren {1965, 1966) 
discussed the prognostic significance of penicillin serum levels in clinical 
medicine in terms of drug-protein interaction. He indicates that drug serum 
levels can't be relied upon exclusively for predicting efficacy. Warren em-
phasized that the extent of binding, such as percentage bound, should be dis-
tinguished from degree because the degree or affinity appears more related to 
activity. The author theorizes that "therapeutic efficacy is probably less 
dependent on serum levels and extent and degree of serum binding than on dis-
tribution in tissues, parencleyma.tous organs and body fluids". Yet, he neg-
lected to consider points stressed in the work reviewed. One of these major 
points is that protein binding, because of its reversibility, not only in-
11.uences drug distribution but affects diffusibility, tissue accumulation, and 
rate of inactivation. And, it is these very factors which Warren deems more 
relative to therapeutic efficacYtthan serum binding. 
The degree or affinity to which penicillins interact with serum and serum I 
i 
' 
albumin was reported by Keen {1965, l966a, l966b). In 1965, Keen reported on j I preliminary experiments in ~hich he demonstrated considerable species varia- I 
.. :_ .... _ -25- _ _J 
tion in the binding of phenethicillin, phenoxymethylpenicillin, and benzyl-
penicillin. The highest percent of penicillin was bound by horse pl.asma, 
followed by goat, ox, sheep and pig. Keen attributed the differences in 
alllount of drug bound to serum aJ..bumin concentrations, differences in drug 
molecule affinity and variations in plasma ionic concentrations together with 
differing competing substances present. Keen (1966a) determined that phenoxy-
methylpenicillin has a primary binding site number and association constant 
of 0,78 and 2376, with secondary sites numbering 86.8 and an association con-
stant of 16.2. These vaJ..ues, Keen continues, predict that 64% of the drug 
would be bound in vivo which agrees nicely with the extent of binding in vitro 
The reason for one site having a predominant affinity was explained through 
reinforcement by van der WaaJ..' s forces, while aJ..bumin flexibility accounted 
for binding of numerous different agents with a high degree but l.ittle selec-
tivity. In this work, Keen care:f'ully and clearly described the methodology 
and mathematic formulae necessary to conduct drug-protein binding studies. 
He discussed the influences of unbound ions of buffer solutions, electrostatic . 
I 
forces, Donnan equilibrium effects and space occupied by solutes upon the drug-1 
albumin complex. Keen al.so reported (1966b) that phenol red, phenoxymethyl-
penicillin and sulpha.metho:xypyridazine could be effectively displaced by sev-
eraJ.. anionic drugs such as phenylbutazone, saJ..icylate or tolbutazmide. The 
anionic displacing agents showed some selectivity. In his conclusion, the i 
author states: "If a substance is highly bound in plasma, the displacement of 
I 
only a small per~entage of it frf>m the proteins will bring about a significant ! 
increase in free drug concentration". He cites bilirubin;..aJ.bumin binding dis- i 
! 
placement by sulfisoxa.zole, resulting in increased incidences of kernicterus 
. 
· in premature infants as on~ of several exo..11ples. ! The publications by Keen are l i ........._,~ -.-.-,. r ,.,_..,._,,,,..,,_ __________ ,,._ . .,_'<,'T•·~~·....,.,,,,..!,_ 
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81110ng the very few good papers involving the interaction of drugs with serum 
To re-emphasize the transport-distribution role pla\yed by serum proteins, 
Mirkin et al (1966) studied the binding of tritiated norepinephrine by plasma. 
After examining the results of their in vitro work using blood taken from 
healthy volunteers, this group suggested that a specific protein, possessing 
eiectrophoretic migration characteristics quite distinct from albumin in human 
plasma, transported some circulatory catecholamines from sites of release to 
their sites of action by binding the catecholamine to the protein. This cat-
echola.mine-protein complex in blood serves as a.protective mechanism, making 
the catecholamines unavailable for biotransformation. 
Krasner and Mc.Mena.my (1966} studied the binding of indole compounds to 
bovine serum albumin. They found a definite change in the binding of indole 
ligands which was consistent with the simple ioniaztion process of the pro-
tein between pH 7. 5 and 9. 5. They also reported a reduction of albumin-ind.ole 
binding in the presence of fatty acids. However, they found no discernible 
differences in the binding affinity of crystalline and Fraction V albumin. 
Krasner and McMenamy, however, pointed out specific differences in the bind-
ing properties of human (HSA) and bovine serum albumin (BSA), dependent upon 
the drug employed. The acetyl-1-tryptophan-BSA complex was stronger than the 
HSA complex, while the reverse was observed with 1-try:ptophan and skatole. 
On the other hand, BSA botind skatole and acetyl-1-try:ptopha.n with essentially 
the same degree, suggesting that the acetylanino and the carboxylate ion 
(-coo-) groups of these drugs are better accol:llllodated at the BSA binding sitesl 
! than at the HSA sites. 
I
i 
L-tryptophan is an essential amino acid partially responsible for the 
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J118intena.nce of nitrogen equilibrium in young humans, growth of human tissue 
culture celJ.s, a.nd for growth in the ra.t. Because there is no mechanism for 
storing nitrogen, the essentia.l amino acids must undergo degradation or be 
used for protein synthesis within a. short time after ingestion (Geyer" 1965). 
The previous work by l:lcMenamy and his associates 1ed investigators to contem-
plate the possib1e re1a.tionship between the l-try:ptopha.n-a.1.bumin comp1ex and 
disease. 
In 1969, McArthur a.nd Dawkins examined the effect of sa.licyla.te on the 
binding of 1-try:ptopha.n to human serum proteins and bovine a.lbumin. They 
found that the presence of increasing concentrations of sa.licy1a.te proportion-
ally eievated the concentration of free, unbound amino acid. The course of 
their investigations led them to consider the possibility that a. portion of 
sa.licylates' anti-inflammatory activity wa.s mediated by try:ptophan. Pursuing 
this a.venue of thought, McArthur et a.l (1971) studied the association between 
1-try:ptopha.n-a.1.bumin binding and rheumatoid arthritis. Their work demonstra.-
ted that the concentrations of bound a.nd unbound try:ptopha.n was significantly 
reduced in the serum of patients with active rheumatoid arthritis receiving 
a.ntirheuma.tic drugs a.s compared to normals. After removing the a.ntirheumatic 
drugs and amino acids from pooled patient sera by ultra.filtration, they added 
try:ptopha.n. Then they determined the binding of the amino acid, a.lone and in 
the presence of sa.licylate, to the sera. When compared to normal sera, they 
found that the tryptophan bound to the serum proteins in the patients sera I 
! 
' was less easily displaced by sa.ticylates. Phenylbutazone, indomethacin, pred- ! 
nisolone, chloroquine a.nd gold were a.lso reported to interfere with the tryp- I 
top~3.Il-protein complex. From these results a.nd other findings, the authors I 
I 
theorized: "When drugs bind to circulating albumin, they displace other bio- I 
i 
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iogicaJ.ly active small molecules from their binding sites on serum proteins. 
The present work shows that this displacement extends to dipeptides which bind 
to human serum proteins. It is suggested that the unbound forms of some pep-
tides ma;y exert a protective effect a<;ainst the actions of mediators of chron-
ic inflam."!18.tory insults. The binding of these hypothetical peptides to cir-
culating proteins may be abnormally strong in patients with the rheumatic dis-
eases because in such patients the circulating albumin possesses an abnormal 
amino acid composition. The fraction of the peptides present in the free form 
would then be insufficient to exert a protective role. It is proposed that 
the antirheumatic drugs act by increasing the proportion of free peptides in 
the blood." Although this theory ma;y be controversial, it is interestingly 
novel. 
The plasma binding effect of proteins on insulin activity in patients with 
acute epidemic hepatitis as compared to normal subjects was discussed by Lei-
bush (1966). The author found potentiation of "'free' insulin-like activity" 
in patients with acute hepatitis traced to an increase in the "free" insulin 
blood fraction coupled with a reduction in the fraction bound. Leibush care-
f'ully noted that the insulin activity cha..~Ges were the result of fraction re-
distribution as opposed to total plasma elevation. Leibush suggests that 
plasma of patients with acute hepatitis is capable of increasing the activity 
of "free" insulin. Hence, Leibush has presented aJl e.'Cemple in which a disease 
has altered the pharmacological effects of a horr:lone by influencing the normaJ.. 
dri.10-protein relationship. 
Gurry (1970) exa."tlned the protein bind.in~-; of chlorpromazine, emplo:yinc 
pla.sr.1a obtained f'l·on circulatinc blood of docs, rabbi ts, and rats. He clrn 
conducted in vivo and in vi'tro bindin.::; c:-.'"I'erinents e:~'ployine psychiatric :pri.-
I 
I 
I 
l 
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tients suf'fering from schizophrenia. CUrry found that therapeutic con:centra-
. tions of chlorpromazine were highly bound to plasma proteins and that . the var-
iation between different humans was marked, 91-99.~. As drug concentrations 
-were increased, Curry observed an increase in the unbound chlorpromazine fl'ac-
tion, indicating binding site saturation. Finally, Curry found significant 
species differences in chlorpromazine binding in the descending order of dog$ 
rabbi ts rats. However, the percentage of chlorpromazine bound to human plasm 
proteins spann~d the range of the percentage drug bound by dogs, rabbi ts and 
rats. As previously indicated, some investigators have shown species differ-
ences in drug binding; however, here we see a. rare report of intraspecies 
arug-protein variation. Unfortunately, Curry did not attempt to explain the 
reason for this variability. 
There seems little quest:1.c!1 that dr-c:.:;; interaction with serum proteins, i.e. 
protein binding, can alter or modify drug distribution clinically, thereby in-
fluencing the dose-response relationship and the rate of drug elimination. 
Based upon theoretical models derived mathematically, Martin (1965) presented 
a s:irnplified, qua.11titive. visualization for est:irnating the influence of drug-
protein interaction of pharmacological activity. Martin feels that the ¢ent 
to i-lhich a drug is bound is dependent upon concentration and affinity. . He 
indicates that the affinity value or apparent association constant (k) should 
be greater tha."1 l x 104 be:fore binding ·will have an appreciable effect upon 
dru[; distribution. Using K 104, he indicates that although as much as 83-~ of 
the drug in t:i1e :plaz:-,10. rlzy be bou.'1d, 73;~ of the total cl:rUS dose may be in the 
t 
m1bound for:n in both plasr:ia and. body water co::i:£>art:"1ents. Although Martin's 
~ 1:-or:: provides a com·e•1icnt ysxdstick, un:forttm9.tely he did not consider t!1e I bindin;; ot extravcs onlo.r <""'1 by other proteineeious elements, pH varioti one, 
L...~~~~--~~~~~~--~--~~--~~~~-~~~--~------------..---~~--...i 
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or changes in albumin concentration. However, he was careful to emphasize tha 
there is a dosage-range within l·lhich small increase in the dose cou1.d produce 
relatively large increase in the concentration of free drug which -Oould result 
in a potentia.ted biological response. 
Weder and Bickel (1970) studied the inte~action of imipramine, d.e-sil:lramine, 
and 3-chlorodesmethylimipramine with human and bovine plasma proteins. Accord 
ing to their results, the drugs were bound primarily by albumin up to 7CYfo us-
ing drug concentrations within the therapeutic range. They estimated the af-
finity of imiprru:tlne to be 104. Folloldng Martin's outline, Weder and Bicke1 
have stated the improbability that protein binding would influence the pharma.-
codynamics of imipramine. Again, it is regrettab1e that the aforementioned 
para.meters were not considered prior to drawing conc1usions. 
Extensive studies of the coumarin anticoagulant drugs and their pha.rma.co-
logical. activity have been published by O'Reilly, Aggeler and their collabor-
ators from 1962 through 1968. In 1962 and 1963, O'Reilly et a1 determined 
that the gastrointestinal. absorption of the drug was rapid and complete. 
They found a relationship between warfa.rin plasma concentrations and the pro-
tll!'ombinopenic activity together ·with an exponential. decay for drug disappear-
ance from plasma. O'Reilly and associates found a correlation between biolog-
ical activity and elimination rate - the slower the rate of.elimination, the 
I more pronounced was the depression of prothrombin complex activity. Prothrom-
1 bin tirne variations amens norr.iaJ.. subjects receiving similar doses appeared to 
; be conditions of elir.J.n::i.t:!.on ra~e differences, wnilc the VlOlum~ distribution 
I . . . 
(:ipprox:i..'1lately 13'~ of body iiCiGht) of the drug was equal ltlth that found for 
. :pcu·e albu:nin. E:·11Jlo;:rinG 11~C-labcled wJ.!'f'arin, they f0tmd that approximately 
er·' of the d:n:1.: 'lms bou.nd. -l:o tl:c n_ lasma alblUain fraction. Their results 
.-'I,, ~ -
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· concerning the association between wa.rf'arin and aJ..bumin led O'Reilly .. a.nd 
Kowitz (1967) to investigate specifically the human serum aJ..bumin warf'arin 
complex. The authors found a. single strong albumin binding site for warfa.rin, 
plus a secondary cla.ss of severaJ.. sites having a much lower degree ot affinity 
since circulating aJ..bumin acted a.s a temporary depot 'Which is in equillbriUlll 
with the unbound-active drug, the authors postulated that the warfa.rin-aJ..bum.in 
interaction influenced the degree a.nd duration of drug activity. Furthermore, 
binding was t~ought to protect the body against a sudden and full pharma.colog~ 
ica.1 effect. In the absence of binding, the unmetabolized drug 'WOuld be more 
rapidly cleared by glomerular filtration a..."ld metabolism, thereby decreasing 
the duration of activity. O'Reilly suggested that the degree or affinity of 
the aJ..bumin binding process accounted for the absence of warfarin from ery-
throcytes, CSF, and urine. Warfarin had a volume distribution identicaJ.. to 
that of aJ..bumin. 
In 1967 and 1968, Aggeler, O'Reilly et aJ.. reported oµ the clinicaJ.. poten-
tiation of the warfarin prothrombinopenic effect by phenylbuta.zone. Earlier, 
f Weiner (1964), Burns (1965), and CUcinell et at (1965) proposed that the in-
~··. 
hibition of couma.rin hepatic metabolizing enzymes.by pyrazolone compounds 
might enhance the anticoa.:.,aulant effects of coumarin drugs, while Brodie (1964) 
theorized about the displacement of warfarin from plasm.a proteins. This dis-
placement, Brodie stated, would make more free warfarin available at its site 
of action. .Agseler and associates, using e~J.ilibrium dialysis experiments, 
provided evidence sno1:inr, pheny~butazone displacement of warfarin from albumin 
binding. A;:;cclcr indicated that this data supported Brodie's hypothesis. In 
1 1S66, Cicinell ~'1d <1.ssocit'.tcs rcrortcd on the death of a cardiac .patient being 
I [ j treated with bisl1~'c'..ro:-:ycoc-'"•9.!'in, who was also treated with chloral hydrate. 
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file authors postulated tha.t chloral hydrate ca.used an induction of the enzymes 
1f'bich metabolized the anticoagulant. They assumed that th~ hypnotic stimulat-
ed enzyme induction similar to that reported by Conney ~ !!, (196o). They at-
tributed the death of the patient to the discontinue.nee of chloral bydrate 
therapy which reduced the bishydroxycoumarin catabolizing enzymes. This, they 
reasoned, led to elevated anticoagulant activity, subsequently resulting in 
massive hemorrhage. Prior to this, no decrease in bishydroxycoumarin effect 
was noted during chloral hydrate therapy. 
A thorough ~ vitro and ~ ~ study examining the interaction between 
wa.rfarin, chloral hydrate, and human serum albumin was conducted by Sellers 
and Koch-Weser (1970). Their data contradicted the conclusions drawn by 
CUcinell ~ al and indicated that the enhancement of coumarin activity was 
most likely due to displacement from binding sites. They emphasized that the 
important difference between enzyme induction and displacement from protein-
binding sites as ca.uses of a shortened half-life of warfarin is that enzyme 
induction must be accompanied by a. decreased hypoprothrombinemic action. In 
contrast, displacement of warfarin from protein-binding sites during there.-
peutic use will cause potentiation of its action. This crucial observation 
represents a milestone in the field of drug-serum protein interaction. 
Sellers and Koch-Weser were able to associate directly the clinical effect of 
a drug to its serum protein interaction. 
In response to the Sellers and Koch-Weser findings, Dr. Garnham, Vice 
President-Medical. Affairs of Abbc5tt Laboratories, wrote physicians apprising 
them of this information. In his letter he indicated the necessity to care-
fully monitor patients receiving warfarin, especially whenever any drug is 
. 
added or withdrawn from the regimen of a patient. Dr. Garnham stressed that ! 
I 
·---------------------------------=>···-·-..... 
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In the presence of the extensive -work 'Which has been done in the field of 
drllg-protein interactions, an attempt has been made to outline the appropriate 
events in some chronological order. Protein bindine has been reviewed from 
the initial observations, through basic research, to the application of its. 
influence directly in the individual patient. Some of the theories of Storm 
van Leeuwen have borne fruit; work by McMenamy s:uggests that runino-acid-
protein interaction r.ucy- be a factor in certain growth processes. Now in the 
field of drug-serum protein interaction, a.n·even more complex a.nd perplexing 
challenge is further stinulatins investigation. The new problem deals idth 
the effects of multiple drus therapy in patients. This new challenge ha.s been 
best summed up by Weiner (1970) • He suggests that many drugs are effective 
by bei!l[; a catalytic reagent or, through a chemical interaction with endogen-
ous hormones, neurohumoral tran'>i'itters, e::iz;1ne co-factors, etc. He stresses 
tha.t both the equilibrium status and 1d.netics of the binding competition in-
flucnce the pharnacolor;ictl activlty of a drur;. In this a.::;e of drug therapy, 
felr patients escape si.-r:iult:meous treatment with n.ore than o::ie drug. Weiner 
concludes: ''·ie a.re still a lons way from a.cco:c::ilishil13 opti.-r:ial treatnent for 
nm-iy patients with a sin::;le, :perfectly tillored dxu:;. Th:is, our t;oal ca..'l.not 
'"C", i "-'--; C",,'" be ',..,~e ._..,.,.1· e,,,_ -·" ,-'!,.,,.,.' b'u'· 
- ....__.....,") IJ- ~J '-'•.1. J:!.._.V .1. ... V, -.......11..1.- '-'-'- .,..,..J >J' rc;ti1er, a..'l e'rer increa.sinc 
1:.:."1~rlcJGc of 11ol: drt~~:: r:i:;l!t intern.ct so -:11.~t lre cc.n tailor our t11crapy t"?.Cco:=-cl 
CHAPTER 2 
STA'IEMEHT OF THE PROBLEM 
During the yea.rs 1937 a..11d 1938, Merritt, Putnam and Schwab introduced the 
eyd.a.11toin group of anticonvulsant-a.ntiepileptic druGs. Of this group, diphen-
yll1ydantoin l·ras considered the most pro::iising. The authors studied the a.nti-
convulsive properties of diphenylhydantoin against electrically induced con-
vulsions in cats. They reported that 200 mg. of diphenylllydantoin a.dmin-
istered orally provided protection against such convulsions. VeT'J impressive 
lras the fact that this provided protection itl thout causing symptoms of na.r-
cosis. 
Since its initial debut, diphenylllydantoin (DPH) has been found effective 
in grand oal, focal or Jacksonian, and psychomotor seizures. T'ms broad 
therapeutic usei'ulness has led many experienced clinicians to accept DPH as 
"the d.."'Ug of first choice in all forms of' epilepsy except those of the petit 
o:W. croup" (Trn::1c..11, 1970). Due to its widespread '1se, DPH has been the subject 
of intensive research a..11d speculation, and this has been discussed both in 
r scientific c.."l.d lay literature. Recently, Bo5ach and Dreyfus (1970) :published 
f a co:-,rprehensive biblio:;raphy a.11d review entitled "The Broad Ra.n.:;e of Use of 
t. 
' Di:PhCI'.yJ.hyd::?.r...toin". 
ic:J. ap:r>lications of 
°I1'lis review cites so:;1c 750 references covering the clin- 1. 
D?.H. The review includes cl1c."':listry, absorption and ex-
c.:.'1d r:.curo_p:.ysiolo;ico.l 1:1ech:?.:rl.c:.11s of action, together 
1
1 
~;-iJv:1 t11c cn.~17 a....11d bindi1lG of DPI-r in ·tl1c b::."o.in. 
I 
! 
bioc11c::-.tlc ::W.. 
A:io:1g invcsti:;c;tors ac'~hre in D:i?!I resc:::rc:'.:. h::.vc been Dill and o.ssociatcs 
(l'~J·S), ?le-.~;, ~:(l Iiinc (1:;5.,J), s~.ren~;.1~--}~ a-~cl :~istcnsen (19G3), i.:~ino (l:'G)), 
'---·,..,·~--- ---------------·----------
(1966, 1968). These workers developed chemica.l and spectrophoto-
,~ i metric analytical procedures :for the determination o:f DPH by itself and in 
L 
DPH-phenobaxbital r:tixtures both ~ ~ and~ vitro. Noach~~ (1958) 
·studied the distribution and :fate o:f DP'.d in rat. Using 14c-labelled DPH~ 
they determined the order o:f arue-tissue concentration in terms of tota.l dose 
a.dnd.nistered 3 minutes after intra.venous injection. This was - liver 19.2%, 
bra.in 15.%, lddney 14.8%, plasma 14.4%, salivary gland 13.5%, fat 11.5% and 
muscle l0.6%. After 4 hours, the drug concentrations remained essentia.lly 
t..l:le saine except that liver, ld.d.ney, muscle concentrations rose, plasma re-
mained stable, ·while the other tissues declined somewhat. The authors re-
ported that DPH a...11d its metabolites Were both absorbed a..'ld excreted by the 
gastrointestinal tract. In 1961, Loeser studied the metabolism of DPH clin-
ically. Blood sa.':Iples from patients receiving a constant regimen of DPH 
averaged 9.5 /cc., with blood levels varying directly 'With dose. Kemp and 
Woodbury (1971) exa.'nined the subcellular distribution of 4-14c-Diphenylhy-
dantoin in the rat brain, specifically the cerebral cortex. These investi-
go.tors fou..11d that DPii easily gained access to the cerebral cortex 'With the 
r;reatest a,'":l.01L."lts bei!10 bound to the microsomal :fraction 12 hours after intra-
thecal ad.-ninistration. 
The field of drU[; bioava.ilability has become of major go-\rern.11ental inter-
est 'Within the last few years. Irrespective of this, the attempt to relate 
d.rt"tG action with plo.s:uo. levels has been on ever-present scientif'ic interest. 
B'..:.chtal ~ t'.l (1960) reported a r~ru:::1 level req_uircr::ent of 10-20 J' /ru. DP!I 
for clinical control of sci::::u:::-cs in r;ra.nd moJ. patients. Acute pronounced side I 
e:fl'ccts l:ere noted in po.tic:::ts with s2r1u:1 levels above 30 ~ /:.u., while none 
1:-erc i::ccn ::..n concentration; below ll; r /.11. Kutt and co-worl~crs (1s;G4) _.,.,.,.:::("\ ,1. ..... ~· ........... 
i ~---~~---- ---------~- ----------,---.,._... ... ,.._..~ 
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a :t:lOre detailed account of the relationship between DPH blood levels, and toxic 
symptamology in epileptic patients who were displaying signs of DPH intoxica-
tion. The authors reported observine nystae;mus when DPJI blood level,a apeo 
proached 20 '(/ml., ataxia at 30 y /ml.., and mental slowing at 4o 1 /mi. Al-
though blood levels in excess of' 6o ({/ml. were obtained without obsel"V'Jln8 
disorientation, Kutt £! ~ warned that accumulation of the unmetabolized ,drug 
systemically should be avoided since reports in the literature indicate that 
large doses of diphenyll1ydantoin may have produced permanent nerve celJ. injury 
in the cerebelJ.um. Damage to neurons ha.s been observed in experimental ani-
mals who were given la.rge amounts of diphenylllydantoin, i.e., up to 20 mg./ 
Kg. or more. Emphasizing this point, Laubscher (1966) reported the death of 
a 4-1/2 yea:r old girl due to the int;estion of 2 grams of DPJI. A blood sample 
taken 24 hours a.:f'ter onset of symptoms revealed a DPJI level of 94 N /ml. The 
average suggested oral therapeutic dose for DPH is 300-4oo mg. per da;y for 
adults, 1.W.ile one-third of this dose is considered safe in children under 
4 years of a(?;e (To:nan, 1970). Adults receiving 600 mg. per da;y veri.J often 
exhibit Si611S of' drug intoxication. Buchthal £! ~ (1960) reported "that 
5-8 ng./KI!,. was necessary to obt::in a serum level of' 10 ~/ml. - 20 i /ml."• 
These levels were obtained in patients 1·1ho had been receiving diphenylhydan-
toin at a daily dose of 350-550 mg. per 70 Kg. for two to three weeks. On 
the other hand, hos:Pitilized patients receiving DFrl for six months maintained 
the srune blood levels ta.1d.r<; 3-5 nr;./K;:,. per dey. This dosage incongruity 
lm.s attributed t9 the consider::i.IDe time necezso.ry to attain steady DPH serum 
co!lcentr:i.tion. 
l'··-"·- =:g· - ··~~--l 
[ 
, about the relationship betvreen serum proteins and diphenylhydantoin. Unfor-
tunately work involving the association be~reen serum proteins and DPl:I has 
just begun. To date a review of the literature has revealed few detailed in-
vestigations concerr.ing the binding of diphenylhydantoin Na by serum albumin. 
Lightfoot and Christian (1966) using radial immunoelectrophoresis determined 
. that diphenylhyda.."ltoin is bound to albumin and 2-globulin. Barlow et !1,, 
in 1962, studied the usefUlness of gel filtration techniques as a tool to 
investigate plasma binding of diphenylhyda.ntoin. ;i:n, vitro dialysis work by 
roeser (1961) indicates that a 43 human serum albumin solution binds DPH pro-
I· · portional to the albumin concentra.tiono. Unfortunately, Loeser' s work did not ~· 
r 
r· 
l 
!. 
indicate the drug concentration or the buffer used. Firemark et al (1963) 
--
found that equilibrium was rapidly achieved betvreen the unbound concentration 
of DPH in cerebral spinal fluid, plasma. and bra.in fluids. Conard ~ al 
(1970-1971) reported that human plasma. bound. 90-95% of the DPH present in the 
serum :fraction 'While rat plasma. bou.."ld 88-90%. These authors used total DPH 
concentrations of 5 to 125 mcg./mJ... Finally, Rudman ~ al (1971) attempted to. 
characterize the binding of DPH by bovine, rabbit and human serum albumin. 
Unfortunately, the solubility characteristics of the drug in their dialysis 
syste."!l allo""Vred these inves·i;igators to determine only the nK intercept. 
Several investigators have observed the interaction of diphenylhydantoin 
with other drugs. An American P'na.r.naceut:i.c.'.ll Association mono&raph discusses 
the findin,r;s of Cucinell .£i al (1963, 1965), Frey ~ ~ (1968), Weiss a.nd 
Hcffeli':i.ngcr (19ti8-1969), Buch~"l, D:i.c.':1.ond and associates (1969-1970), Kutt 
: ct ~1 (1969), 
,--
end Kristensen ~ .'.l1 (1969) conccr!'.ed with DPH-phenobarbital 
Ii -in"- 0 r.,cJ..1·on _ ... v,_ ..... v ... • The rlono;:;rn.ph su::n::>ri:::es this wor:,, st:>.t:i.ng: "Phenobaxbital 
i . 
' j :1zy 1. ncrcn.se, 
~ -·~~---~~--~-~--~~---~-8--~------~------------~----~--~....i 
dccrea:::e, or c:iuse no cho..'1..:;C in di!'hcnylhydantoin blood level:::. 
··· . concontl tant phenobarbi taJ.-diphenylhyd.antoin therapy is clinicaJJ.y justified 
and has not resulted in increased toxicity or loss of control of the .epileptic 
; patient." Con~rsely, Solo:ma.n and Schrocie (1967) reported a.n increase in the 
mean bioloi;icaJ. half-life of DPH from 25 to 55 hours in patients receiir.tng DPH 
and phenyramidol concurrently. These authors stated: "In patients taking 
both drugs simultaneously, elevated plasma concentrations of diphenylhyd.antOin 
cou1d account for the increased anticonvulsant effects observed". The authors 
indicated that phenylramidol interfered i·tlth DPH metabolism. According to 
the findings of Scriabine et aJ. (1970), DPH protected dogs from digoxin-in-
duced ventricular arrhythmias without significantly modifying digoxin lethaJ.-
On the other hand, digoxin protected the anima1s from DPH-induced myo-
cardiaJ. depression and hypotension. 
Careful search of' the literature has not disclosed any studies involving 
the binding of DPH to serum proteins in the presence of other drugs. In fact, 
relatively few researchers have studied the effects of drug mixtures upon 
serum albumin binding of the individua1 dxug entities. Among the drug pairs 
t..'fiat have been exa.."lined a.re barbiturates (Goldbaum and Smith, 1954), tolbu-
tamide a.."ld insulin (Haselblatt, 1963), penicillins and pheeylbutazone, sali-
cylate and sulfona..-nides (Robinson a..>id Sutherland, 1965), sulfonamides (Anton, 
1961), penicillin G ir.i.th probenecid (Fish!nM, 1964), penicillin with sulfon• 
e.r.tl.des, sa1icylates, etc. (Kunin, 1965), and warfa.rin id th salicylates 
(Zn.roslinski. ·!:i Ed:,, 1971). Most of these investi:;ators reported displacenent 
of one dru:.'; entii;y f'rou aJ.bumin ""j· the presence of the second drug. However, 
the in vitro worl~ of Zn.roslinsl:i end coll::i.bor::i.tors reveaJ.cd broader phenomena. 
. t t• ti concen ra ions • Za.roslinski ·~ al reported a decrease in the number of war-
fa;rin-albumin binding sites and association consta.nts·in the presence of 
A majority of the protein binding work involving drug mixtures ha.s con-
, cerned a..>itibiotics. In addition to single drug dosages, DPH is available 
) therapeutically for epilepsy in a combination of DPH 100 mg. - phenobarbital 
and 6o mg., and DPH has been used as an adjunct with trimethadione. 
Goldstein (1949) and Meyer and Guttman (1968) include over 850 references 
in their reviews on drug-protein interaction. Of aJ.l the work done in the 
! field, only a smaJ.l percentage was concerned with a comparison of drug-protein 
j binding between mammalian species. Much less ·work has been done to investi-
• gate the in vivo therapeutic potency of. drugs during physiological states of 
Anton (1960) and Genazzani and Pagnini (1963) deter-
·mined species differences in the binding of sulfonamides. In 1962, Wishinsky 
~al noted species differences in binding of 4 sulfonylureas by bovine, 
httna."l, dog, horse, pig and rat albumin. The percentage o'£ a ef ven concentra- · 
tion of drug bound to plasma of various ma.nnnalian gpecies for three penicil.1-
ins wo.s reported by Keen in 1965. Diphenyl, phenox;ymethyl, and benzyl peni-
cillin were shown by Kunin (1965) to be more hig..'ltl.y bound to human serum than 
rabbit serum. Robinson and Sutherland (1965) determined species differences 
! in eer-..nn bindi:n.:; of bencylpenicillin and cloxacillin. Conard and his asso-
' [ ciates (1970,1971), i·ntlle comparing the percentage of DPH bound by h~la.!l a.nd 
rat plumr:.a, re:ported th:>.t spccioo difference resulted in hiaher f'ree d.ruc 
levels in rat plasr:11 :-· .:'..'1 in human plasma. T'ney attributed this to the fact 
that ti.1e perccntr-..:;c of :il1.J'ti:r.tln in the t1-;o plas:n:i. sources e.-:iployed differed. 
TI:c rat plamc.a protein i'r:.i.ction consisted of appro:d.."'lately 31'.j albu=.rl.n i·;hile 
------,-~------·----------- ·---.---1 
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the human plasma protein fraction was approximately 43%. 
Rudman!:!,!!:! (1971) determined the binding site characteristics.of sali-
cylate on human and bovine serum albumin. Their work revealed a similar mun-
ber of binding sites and binding site classes for both albumins; however, the 
association constants for each class of sites for salicylate on bovine serum 
albumin was from four to ten times greater than that for human serum albumin. 
Although only able to determine nK intercepts for DPH, Rudman and associates 
showed that the total nK values for the albumins differed, being ll,000 for 
HSA and 14,500 for BSA. 
While stucying the effects of pH on drug action, Waddell and Butler (195 
were able to show that the median anesthetic dose for phenobarbital in mice 
was 20% higher after NaHC03 induced alkalosis. Waddell and Butler also stated 
that phenobarbital blood plasma concentrations rose as the pH.rose, a.nd fell 
as the pH fell. 
The purpose of this stucy is fourfold. The work will endeavor to deter-
mine and compare 
I. The binding characteristics of human and mouse serum albumin in 
relation to diphenylhydantoin sodium (DPH). This work appears to 
be the first attempt to investigate thoroughly the binding charac-
teristics of DPH to serum albwnin and compare binding differences 
between two species, providing they exist. The data obtained 
together with information in literature should be useful in provid-
ing insight to a better under.standing regarding the importance of 
' the characterization of primary and secondary binding sites. 
Sunshine (1969) in "Handbook of Analytical Toxicology" provided 
data and numerous references which show the association between 
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blood concentrations of phenobarbital, diphenyl.hydantoin, and 
other drugs, a.nd pharmacological and toxicological effects. ·Norm-
ally, binding site classifications and association constants are 
determined from a graphical presentation of the data obtained from 
plotting a range Of drug concentrations. The drug concentrations 
usually range between a serum plasma level which has no pharmaco-
physiological effect to levels far in excess of those i'ound to cause 
death. If the data plot is a curve, then more than one class of 
binding sites is considered involved. Work done to date has not 
considered the fact that drug binding to serum proteins can only 
have pharmacological implications when the drug concentrations used 
to characterize binding remain in a range which is less than drug 
blood levels found at death. If the binding data. results in a plot 
which is a straight line at serum levels below or at those found at 
death, then it is likely that only one class of binding sites prevails 
In this situation the primary or single class of binding sites and its 
association constant might conceivably determine the pharmacological-
toxicological implications between a. drug and its binding character-
istics in situ. 
--
II. The work will attempt to show changes in serum drug levels, brain drug 
levels and drug availability relative to DPH a.nticonvulsa.nt activity 
in mice during normal, acidotic, and alka.lotic states. Hopef'ul.ly, the 
pH-drug potency data Ca.I\ be reconciled with the effects of pH upon DPH 
binding to albumin, determined during ~vitro binding experiments. 
III. Experiments will be conducted to obtain information concerning human 
serum albumin binding of DPH in the presence of other drugs which 
-42-
might be related to its therapeutic availability or potency. ·For 
this purpose, four drugs have been selected which should generate 
information concerning the effect of drug combinations upon serum 
albumin binding of DPH. These drugs are phenobarbital., trimetha-
dione, phenylbutazone and warfarin. Phenobarbital is a drug possess-
ing similar therapeutic activity and is used clinically in combina-
tion with diphenylhydantoin. Trimethadione is a drug used for petit 
mal. epilepsy and has been employed therapeutically in combination 
with diphenylhydantoin in petit mal. seizures where the EEG contains 
multiple spikes in the spike and wave pattern. Since epileptic 
patients sometimes have been· given drugs possessing analgesic, anti-
pyretic and anti-inflammatory activity, and since many patients do 
suffer from cardiovascular diseases, phenylbutazone and wa.rfarin 
have been included. Bothof these drugs are high1y bound to albumin 
which indicates that they could possibly compete with DPH for binding 
sites on the albumin molecule. These two drugs have not been reported 
to possess anti-epileptic properties. 
IV. Finally, it is the object of this study to discuss the serum albumin 
binding of diphenylhydantoin in connection with its pharmacological. 
utility and consider it in relation to its in ~ anti-convulsa.nt 
activity, 
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CHAPI'ER III 
MATERIALS AND METHODS 
In this study, _!!!vitro a.nd _!!!vivo experiments were designed to explore 
the possible pharmacological and toxicological implications inherent in the 
binding of diphenylhydantoin sodium (DPH) wfth serum albumin. The binding 
characteristics of albumin for DPH were determined by varying specific physi-
cal and chemical conditions. All binding experiments were conducted in an _!!! 
vitro system devised to minimize the binding of ions other than DPH to the al-
-
Although _!!! !!!9. experiments do not deal directly with drug-serum pro-
tein, and/or tissue binding, they were planned so that results would reflect 
indirectly upon in vivo drug-protein binding and pharmacological activity. 
The concentration, a.mount, and percentage of drug bound to serum albumin 
were determined using a modification of the equilibrium dialysis procedures 
described by Karush (1958) .and Zaroslinski et al (1969, 1971). In this equili-
brium dialysis procedure, the protein-drug component was confined in one cham-
ber and separated by a semi-permeable membrane, cupropha.n, from the buffer, 
non-drug component. The cuprophan a.lJ.owed unbound drug molecules to diffuse 
freely between the drug-albumin retentate chamber a.nd the buff er diffusate 
chamber until equilibrium wa.s attained. When unbound, free ~ug concentra~ions 
in opposing chambers became equal, drug increments in protein compa.rt;m,e,nt were 
considered to represent the a.mount of drug bound to protein. The DPH in the . 
buffer retentate was considered unbound, free drug. (See page 48 .for" details.) 
The concentration and perce'nt of drug bound was determined as follows: 
(1) Concentration of bound DPH = Concentration of DPH in the serum albu-
min retentate chamber minus the DPH con-
centration in the buffer retenta.te cham-
ber 
(2) 'fo Bound DPH = Concentration of bound DPH x 100 
Concentration of DPH in serum albumin retentate 
DPH between the dialysis chambers, due to the presence of 
albUIUin, will be slightly influenced by the Donnan effect and the space occu-
pied by proteins and other solutes. Because of these effects, the concentra-
tion of the drug in the buffer retentate fraction over-estimates the concentra-
tion of free drug in the albumin retentate fraction. Therefore, the Keen 
(1966 b) procedure was employed to correct for these variables. Consequently, 
(1) becomes: 
( 3) DPH bound = DPflaibumin x f - DPH buffer x 1. 004 
r 
where f = 100 
(99.6 0.75 (g. albumin/100 ml. 
"This assumes that the specif'ic gravity of albumin is 1.33 a.nd that 0.4~ 
of the volume of the solution is occupied by solutes other than protein." 
Similarly, DPH in the buffer retentate was multiplied by 99~ 6 = 1. 004 to 
. ' correct for solute space. 
Finally, r represents the Donnan correction factor which was determined 
distribution of sodium between the albumin retentate fractions. 
(4) r =concentration Na+ albumin 
concentration Na· buffer 
Keen as well as several other investigators does not adjust binding data 
account for electrostatic interaction. Keen (1966 b) suggests, as does 
Scatchard (1949), that electrostatic correction might be inapplicable because 
anions displace buffer anions from bin4ing sites rather than reacting with un-
' combined albumin. Thus the binding data generated in this work was not cor-
rected for electrostatic interaction. 
It is the conccnsus that this method of equilibrium dialysis, in which 
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equal volumes of solution are dialyzed, provides one of the most accurate and 
uncomplicated methods for the study of drug protein interaction. A1th()Ugh 
this technique of dialysis is time consuming, requiring 12-16 hours to attain 
equilibrium, it allows for the convenience of an overnight bin~ reaction. 
Diphenylhydantoin was assayed using the counting procedure of Ze.roslinski 
and associates (1969, 1971) and Oester ~ ~ (1971). An aliquot of 5,5'-di-
phenylhydantoin-4-14c was added to the albumin-DPH solution in the protein 
chamber just prior to dialysis. After equilibrium was attained, a 2 ml. aJ.i-
quot of the protein retentate was added to one counting vial while a like aJ.i-
quot of its corresponding buffer diff'usate was added to another counting vial. 
In all experiments, counting viaJ.s were prefilled with 10 ml. of Insta-Gel, 
maintaining a 10:2 ratio between emulsion-fluor and sample. For the in vivo 
--
experiments, the blood was centrifuged at 5000 g. , using an International Equ-
ipment Co. Model PR-6 refrigerated centrifuge. One ml. serum was introduced 
into a counting vial together with l ml. buffer. Brain tissues were solubi-
11ized over a 24 hour period in 6-7 ml. Soluene-100, then made up to 10 ml. wi-
1 th the soluent. Two ml. of the digested materiaJ. were added to a counting vi-
i I al. All samples were counted in triplicate for 10 ·min. in a Packard Model 
l, 3380 Liquid Scintillation Counter. The counts were averaged and corrected for quenching, This procedure combined precision, accuracy and reproducibility 
I l 1 with specificity and simplicity for the in vitro and~~ measurement of 
~ I minute quantities of DPH in albumin, buffer, serum and brain tissue solutions. 
: To minimize bindip.g study expermental variance, resulting from extraneous I j variables and pipetting errors, each experimental point was established on the I 
~ i 
: basis of 2 separate e:>..-perir:ients. Since the variation in results between dupl.i-1 
cate experiments was minimal, two e).-periments per point were considered suffi- i 
··--~ ··~-~----=··"---·-"-"·-·~ ... ___ _,,_. ... ····~~----'""-- . ,,,.,_.,,.,, ___ _;__,. --------- J 
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r ...... _______ _____, cient and the results were averaged. (See Appendix, page ll8 for more details) 
l 
Estimation of Sodium. Sodium concentrations were determined in a Coleman 
Model 21 flame photometer interfaced with a Coleman Junior Model 6c spectro-
photometer for percent transmittance readout. (See Appendix, page 121). 
Measurement of pH: The pH of acqueous solutions were determined With a 
Corning Model 7 pH meter. The measurement of blood pH was ascertained with an 
Instrumentation Laboratories Model ll3 ultra-micro blood pH/gas analyzer sys-
tem. 
Estimation of Protein Concentration: Serum albumin concentrations were 
determined following the method described by Gornall ~ ~ (1949). A Beckman 
DU-2 spectrophotometer was used to measure optical density (see Appendix, 
page 120). 
SYSTEM CCMFONENTS AND PROCEDURE 
Unless specified, all solutions were constituted with glass distilled 
water. The binding experiments were conducted using Sorenson's M/15 (0.067M) 
phosphate buffer. Sorenson's phosphate buffer provides little or no competi-
tion between drugs and their binding with serum albumin (Keen, 1966 b}. All 
compounds were weighed on a Mettler Model H2or analytical balance to the near-
est 0.01 mg. 
Dialysis Membrane (Cuprophan, Edwards Laboratories): The semi-permeable, 
dialysis membrane was prepared from sheet material. The sheet material is a-
vailable commercially as Cuprophan and is used clinically for renal dialysis. 
Cuprophan was chosen becau~e the hic;h quality and uniformity of the ma-
1 terial appear to provide the attainment of equilibrium in a shorter period of I time as compared with Visl:ing tubing. Zaroslinski et al (1969) found that 
~~uilibrium occu~:;_ed in a~~~!.~~2 hours using cuprophan in the modified 
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' 
Ka.rush dialysis system. In contrast, they fou.~d that attainment of equilibrium 
required approximately 24 hours mien Visking was empl<;>yed as the semi-perme-
able membrane. 
Discs of cuprophan (40 mm. diameter) were thoroughly rinsed in glass. dis-
tilled water, then placed in the appropriate buffer and refrigerated overnight 
,,.-, 
the evening before each experiment. The washing and soaking was done. to elim-
inate substances in or adhering to the membrane which interfere with the exper-
iment. The discs were placed between the dialysis chambers and trimmed immed-
iately prior to introduction of buf'fer and albumin solutions. 
Dialysis Chambers: Equilibrium dialysis was accomplished employing paired 
5 ml. modified Ka.rush dialysis chambers (Bellico #3221). The two chambers 
were paired by briskly milling· the Wide flanged ends together. If this match-
ing of the chambers is not done, they have a tendency to leak after being 
· placed into the spring clip holder (Bellico #3217). 
Dialysis System Assembly and Procedure (Figure 1) 
1.. A wet cuprophan disc was placed between paired dialysis chambers, ex-
cess material. trimmed to the chamber flanges, and the coupled chambers fitted 
into the spring clip holder. 
2. Using a 5 ml. pipette assembly, 4.6 ml •. of the appropriate albumin so-
lution was introduced into the albumin retentate chamber through the porthole. 
Employing a clean pipette assembly, 4.8 ml. of the appropriate buffer solution 
was added to the buffer retentate chamber. 
3. A 0.1 ml. aliquot of the concentrated DPH solution and 0.1 ml. l4c-
t 
labeled DPH solution was then introduced into the albumin chamber using a Ham-
ilton 1'Iicroliter pipetting syringe. 
4. A 20 mm. square section of Parafilm "M" closure material. (.American Can 
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FIG. 1 
DIALYSIS SYSTEM 
Paraf ilm . 
- Scientific Products) was then sealed over the entry port of ea.ch chamber. 
5. The dialysis system assembly was then placed. into a. metabolic shaker 
and agitated a.t 80 strokedJmin. using a. 1-1/2 inch stroke. The contents were 
thus dialyzed for 24 hours a.t room temperature (25 ±1°C.). 
6. At the end of the dialysis period, 2 ml. of the albumin chamber con-
tents were added to a. counting vial containing 10 ml. Insta.-Gel, emulsion-
soluent fluor. A 2 ml. pipette assembly under vacuum was employed to accom-
plish sample transfer. This procedure was also followed with contents f'rom 
the matching buffer chamber. 
7. The paired' counting vials were then identified and the contents thor-
oughly mixed by gently swirling. 
8. All samples were then stored at 1°C, for approximately 24 hours prior 
to counting. If counted prior to the storage time, the proteins have a. ten-
dency to interact with the emulsion~solvent system, producing excessive chemo-
luminesence which results in erroneously high counts (Gibbs, 1969). 
For additional details, see page 118. 
Preliminary Experiments. Pilot experiments were conducted to determine 
the length of time necessary to achieve system equilibrium and to assure that 
no interference in binding resulted from the system itself. In one set of 
binding experiments, various concentrations of DPH up to 50 'x io-5M were placed 
in the human serum albumin (HSA) retentate chamber while the opposite chamber 
contained buffer only. In a second set of experiments, the procedure was. re-
versed and duplicate concentrations of DP-tl were placed in the buffer retentate 
' chamber. After 24 hour dialysis, the solutions in both retentate chambers 
were analyzed for DPH concentration (see Appendix page ll8 for more details). 
Further experiments ascertained the amount of time necessary to attain 
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system equilibrium. The aforementioned procedure was emp1oyed and the dupli-
cate systems assayed after 2, 4, 8, 12 and 24 hours. Minima.l equilibrium 
time was estimated to be greater than 12 hours but less than 24 hours. Addi-
tional work was performed to insure that neither drug concentrations nor their 
vehicles when added to chamber contents produced any alterations in pH. 
Experiments were conducted to observe,!.!!~ b1ood pH alterations in 
mice receiving nothing, drug vehic1e, DPH plus vehicle, Na.HC03 or NH4C1. 
Neither the drug vehicle nor the DPH plus vehicle produced a.ny alterations, 
while Na.HC03 induced alkalosis and NH4Cl caused acidosis. 
HSA and MSA Diphenylhyda.ntoin Binding Experiments 
The effect of drug concentrati6n variation upon diphenylhyda.ntoin bind-
ing to albumin was studied to estimate the number of binding sites per mo1e-
cule of human serum albumin (HSA) and mouse fraction V serum albumin (MSA) 
ava.lla.ble to the drug. Information from this data. provided a be.sis to deter- . 
mine the intimacy of the drug•albumin association. Drug concentrations rang-
ing from below those considered therapeu~ic to those producing severe drug 
intoxication when measured clinicaJ.1.y in serum were investigated as follows: 
].. J..60 x 10-~ 6. 50.04 x 10-~ 
2. 3.16 x 10-~ 7. 100.05 x lo-5i.i 
3. 6.29 x l0-5M 8. 125.09 x 10-5M 
4. 12.54 x l0-5i.i 9. 200.04 x l0-5M 
5. 25.04 x l0-5M 
The 6.29 x io-5i.1 concentration was employed in all other HSA and MSA experi-
' 
ments. At equi.iibrium, the 6.29 x l0-5M pre-dialysis concentration resulted 
in a serum albumin concentration in the HSA retentate chamber comparable to 
that considered efficacious (14-17 mcg./ml.) as reported by clinical 
-51-
~··· 
(see pages 36-37). This concentration al.so produced a· drug 
concentration in the MSA retentate chamber equivalent to those in mouse serum 
during those experiments where DPH was found to antagonize maximal eJ.ectro-
shock one hundred percent in mice. 
A ratio between the moles of ligand bound per mole of albumin (r) and 
moles per liter of unbound drug (C) was plotted against r. From this curve, 
the number of' binding sites (n) and their association constants (K) were 
calculated according to the equation formulated by Scatchard et al (1957). 
- \"'\ - ~ '°' . riKiC The basic equation is: r ='-'iri ="-'iri = G.; 1 l+Kj_C 
~' where r is the average molar ratio of bound ligand for the ith binding site 
of the protein, n is the number of sites in the ith class of site, and K is 
the association constant for the interaction of the class of site with the 
ligand. The individual n and nK for each class of binding sites were derived · 
graphical.ly following the method described in 1950 by Karush. (See Appendix, 
page 123 for f'urther details.) 
The normal. clinical range for blood pH is 7.35 - 7,45 in humans; "any pH 
below 7,35 or above 7.45 is generally defined acidosis and alkalosis respec-
tively'.' (Wood.bury, 1965). In contrast, the normal range for blood pH in mice 
appears to be dependent upon the strain of the animals used~ Although the 
standard errors were small, Bernstein (1966) has reported pH differences in 
right ventricular venous blood ranging from 7.26 - 7.428 in 16 different 
strains of mice. Thus, it was necessary to fix the age, weight and determine 
' the blood pH of the strain of mice ei:iployed prior to conducting any in vitro 
MSA experiments or in vivo acidosis/alkalosis experiments. The effects of pH 
variation upon serum albumin-DPH interaction were investigated because many 
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acute and chronic disease states clinically produce an acid 8Xld/or base 
disturbance. HSA and MSA equilibrium dialysis systems incorporating the fol-
lowing pH variations were employed: 
1. 7.0 3. 7.4 
2. 7.2 4. 7.6 
~· .All other~ vitro HSA and MSA experiments were conducted at a pH 7.4. 
Since there are clinical conditions which cause blood serum albumin con-
centrations to deviate from the norm, the effects of HSA and MSA variations 
·~ 
" on the DPH-albumin complex were also examined. The following concentrations 
of HSA and MSA were utilized: 
!!§! MSA 
~-
~ ~ ~ 
t: 2% 
4% 
6% 
Due to the difficulty in obtaining large quantities of MSA, the 6% concen-
tration was omitted. AJ.l other experiments were conducted using the 4~ 
albumin concentration. 
Effects of Ligand Competition upon DPH-HSA Interaction 
Seldom does a patient receive a single drug entity to combat illness. 
Thus, it was decided to study diphenylhyd.antoin-human serum albumin int~r- · · 
action in the presence of other drugs. During these experiments,. the second-
ary druG was placed in the buf:r.:er diffusate chamber while DPH was placed in 
the HSA chamber. The following drugs and initial drug concentrations were 
e~ployed for the drug combination experiments. 
a. Phenobarbital Na: 
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1. 6.25 x lo-\i 3. 25 x lo-~ 
2. 12.5 x 10-~ 4. 5 x l0-4M 
b. Trimethadione: 
1. 1 x lo-\i 
2. 2 x lo-\i 
c. Phenllbutazone: 
1. 25 x 10-~ 3. 1x10-~ 
2. 5 x lo-~ 4. 2 x lo-'.\i 
d. Warfarin Na: 
1. 1.6 x 10-~ 3. 6.25 x 10-~ 
2. 3.12 x 10-~ - 4. 12.5 x l0-5M 
These concentrations were chosen because it is estimated that their range 
would produce drug levels in the albumin compartment equivalent to drug con-
centrations found in serum when therapeutically effective. Due to the scar-
city of mouse fraction V serum albumin, the experiments were conducted with 
HSA only. 
Anticonvulsant Effect of Diphenylhydantoin 
Maximal electroshock (MES) experiments were chosen to determine the ef-
feet - acidosis or alkalosis - might have upon the protection afforded by DPH, 
because of end point reproducibility and sharpness. This technique a.J.ao pro-
vided a suitable measurement to which drug serum and brain levels CQUl.d be 
related. 
MES experiments were conducted using the method of Swinyard et al (1952). 
. ' . --
The electrical stimulus was applied through pa.ired, silver corneal. electrodes 
e:nploying the electroshock seizure apparatus described by Woodbury and Daven-
port (1952) as modified in 1961 by Sittig (see Append.ix, page 132 for detuils) 
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· Eight, Charles River cn1 strain, ma.le albino mice, aged 6-7 weeks, were used 
per group. The anima.ls weighed approximately 30 gm. each (30.54 :0.17 S.E.). 
The diphenylhyda.ntoin was administered i.p. one hour prior to MES (50 
milliamp for 0.2 second duration). Each anima.l received approximately 
20.79 x 103 cpm/gm. of weight; therefore, a 30 gm. animal received ap;proxi-
mately 623,700 cpm. Protection against MES was defined as the abolition of 
the tonic extensor reflex. 
Serum and brain DPH concentrations in normal, aJ..kalotic and acidotic 
mice were determined. It was necessary to pool the blood from each experi-
mental group to obtain the appropriate serum volume. DPH brain concentrations 
were determined for each individual animal. Al.kalosis was induced by intra-
peritoneal injection of NaHC03, 1 f!JJl./Kg., fi~een minutes after DPH admini-
stration. Immediately after application of MES, the anima.l was exanguinated 
by decapitation and the blood collected in a centrifuge tube. Approximately 
10 large drops of blood per animaJ. were obtained. Brains were removed and 
weighed on a Federal Pacific roller baJ.ance to the nearest 1.0 mg. Then, the 
brain was placed in the digesting solvent {see page 46). The entire procedure 
from electroshock application to the placement of brain tissue into the sol~­
ent took 2-3 minutes. AnimaJ.s were treated individua.lly at 6 minute intervals 
to provide sufficient time. To limit the effect of circadiilin rhythms and sea-
sonal variables, each series of ~ ~ experiments was conducted between 
9 A.M. and 3 P.M. within a two week period. The median protective doses 
(PD 50) for DPH under the various conditions were calculated in the manner 
' described by Litchfield and Wilcoxon (1949). 
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Human Serum Albumin Solution {Research Products Division, Miles Labora-
tories, Inc. ; Pent ex Lots· #27 and 28. 
CrystaJ.line human serum aJ.bumin, assayed 100% pure electrophoreticaJ.ly, 
was dissolved in the appropriate M/15 (0.067M) Sorensen's phosphate bUft'er. 
The human serum aJ.bumin solutions were freshly reconstituted for each 
experiment. 
Mouse Serum Albumin Solution (Research Products Division, Miles Labora-
tories, Inc.; Pentex Lot #7). 
Mouse aJ.bumin, fraction V powder, assayed electrophoreticaJ.ly to be 99'j 
pure albumin, was dissolved in the appropriate M/15 {0.067M) Sorensen's phos-
phate buffer. Miles-Pent ex states that alpha globulins are the major contam-
inant but alpha-1 acid glycoprotein may aJ.so appear. The mouse serum aJ.bumi;n 
solutions were freshly reconstituted for each experiment. 
5,5-Di;phenylhydantoin Sodium (Sodium DilantinR) - Parke, Davis and 
Company, Lot #407265). 
The appropriate amounts of powder were dissolved in freshly prepared 
0.01 !f NaOH solution prior to each experiment (Conard, 1969). Then, an 
aliquot was pipetted into the proper diaJ.ysis chamber at the concentrations 
indicated on page 51. The drug was also dissolved in those buffer solutions 
which would permit drug solubility while conducting experiments to determine 
system equilibrium. 
5,5-Dipheny1hyda.ntoin-4-c14 {New England Nuclear, Lots 506-130 and 
583-056). 
' 
The labeled powder was dissolved in 0.01 !!_ NaOH and stored refrigerated 
i as a stock solution (Conard, 1969). An appropriate aliquot of the solution 
i l·. I was pipetted into tho proper dialysis ch,,,ber just prior to each experinent. 
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nrugs E111ployed in DPH-Albumin Interaction Antagonism EJCperiments 
Phenobarbital Sodium (Mallinckrodt, Lot .f/!rHP), PhenylbutazOJ:ie (Geigy, 
10t #SN 44921), Warfarin Sodium (Abbott Laboratories, Lot #789-3613}, and 
Trimethadione (Abbott Laboratories, Lot # 788-7314). Each drug was dissol• 
ved in the Sorensen's pH 7.4 buffer solution and a 4.8 ml. aliquot of the 
appropriate solution introduced into the buff er diffusate chamber of the 
dialysis system. 
Sodium Hydroxide Solution (Harleco, #13092). 
Sodium hydroxide soJ.utions were prepared by diluting commercially av-
.a.ilal:>le 10 !! analytical. reagent grade sodium hydroxide solution with glass 
distilled water. A 0.01 ! solution was employed to dissolve diphenyl-
hydantoin. 
Sorensen's M/15 (0.067 M) Phos;phate Fuffer (Hepler, 1960) 
Sorensen's M/15 Phosphate Bu:ffer solutions were prepared at the proper 
pH by mixing the appropriate quantities from stock soJ.utions of: 
J.. M/15 Potassium Acid Phosphate (KH2P04), 9,o8 gm. qs. to l liter. 
(Mallinckrodt, Lot .f/!rSB) • 
2. M/15 Disodium Phosphate (N~HP04 ), 9.47 gm. qs. to 1 liter 
(Mallinckrodt, Lot #XCV) • 
Biuret Reagent (Harleco Lot //9024P) 
The reagent was prepared in accordance with the procedure described by 
Gorna.U ~ ~ (1949). The preparation consisted of a modified aJ.kal.ine 
copper tartrate stabilized with .potassium iodide. 
Ammonium Chloride Solution (N1f11 Cl) (Mallinckrodt, Lot #LUX) 
The a.-:m1onium chloride solution was prepared by dissolving 400 mg. 
Emulsifier-Solvent-Fluor System 
Insta-Gel {Packard Instrument Co., Inc., Lots #19-K-69-o8 and 27 K 70o8). 
counting a constant ratio of 10 ml. of Insta-Gel to·2 ml. aqueous sample 
employed. 
Tissue Sample Solubilizer 
TM Soluene 100 (Packard Instrument Co., Inc.). Description of procedure 
given on page 46. Although heating of tissue and solubilizer speeds up 
the digestive process, most animal tissues require 24 hours for total. d.iges-
tion. Since digestion speed is a function of exposed surface, the bra.in was 
cut into three sections and totaJ.ly immersed in the solubilizer. Bra.in tissue 
was usuaJ.ly solubilized within 18-20 hours. 
Flame Photometry Chemicals 
Sodium Flame Photometry Standard "A", 250 mEq./1000 ml. (Ha.rleco, 
Lot #60301) and Sterox SE (Harleco) were employed in the determination of 
albumin and buffer chamber sodium concentrations. Both chemicals were di-
luted to the proper concentrations using glass distilled water. 
SJ?eciaJ. Pipette Assemblies 
Individual. Hamilton microliter pipetting syringes fitted with Chaney 
adapters {accuracy ±0.1%, reproducibility ±0.01%) were employed to deliver 
or withdraw solutions of 0.0 ml. Syringes were marked and used for a specific 
task, i.e. the introduction of hot DPH into the aJ.bumin chamber, to minimize 
pipetting and counting errors. Pipetting assemblies had to be constructed to 
. allow introduction and withdra'\al of solutions greater than 1 ml. through the 
narrow pipe-like chrunber ports of the dialysis chambers. The assemblies con-
sisted of 5 ml. I-lohr measuring pipettes (accuracy :!:0.02 ml.) or 2 ml. volu-. 
metric pipettes (accuracy :to.oo6 ml.) to which were attached 20 gauge x 1 inch 
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monoject, polypropylene Luer-Lok. hub, sterile hypodermic needles (Scientific 
Products - Sherwood Medical Industries). 
' 
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RESULTS 
Prior to beginning in depth diphenylbyd.antoin (DPH) binding experiments, 
a. series of preliminary experiments were conducted to determine drug recovery 
and efficiency of the dialysis system. It was found that the buffer solutions 
produced no quenching. The recovery was 101.9% (:!:0.23 S.E.) of theoreticaJ.. 
OnlY a very slight quenching effect was observed with the aJ.bumin solutions. 
The cpm vaJ.ues obtained with 4% aJ.bumin in buffer were less than 1.8% of those 
obtained in buffer al.one. 
Experiments were al.so conducted to insure that the administration of 
NaHC03 , 1 f!J!J../Kg. and NH4c1, 4oO mg./Kg. would produce a.lkalosis and acidosis 
in mice. Table 1 shows that the blood pH of saJ.ine injected control animal.a 
was 7 .39 ±o.o. Administration of DPH in 0.01 N. Na.OH did not significantly 
alter blood pH whereas NaHC03 significantly increased the blood pH to 7.55. 
:rnr4Cl significantly reduced pH to 7 .23 when compared with the saJ.ine control 
group. The NaHC03 findings were in agreement with those reported by Wad.dell 
and Butler (1957). 
To estimate the number of binding sites per mol.e of aJ.bumin, the moles 
of DPH bound per mole of aJ.bumin (r) was determined for seve.raJ. concentrations 
of the drug. The possibility that serum albumin of individual. species might 
bind DPH differently was explored by determining r for both human serum al.bu-· 
, min (HSA) and mouse, fraction V, serum aJ.bu.'Ilin (MSA). The r ratios were then 
I ' ! related to the m0la.r concentration of unbound (free) drug (c) present by plot-
! ting r/c vs. r. The molecular weight for HSA was taken as 69,000 (Phelps and 
• 
Putnem, 1960). To our kn.owl.edge, the molecular weight for MSA has not been 
! 
determined; however, Charlwood (1959) approximated a molecular weight of 69,0C:Oj 
r--.·~->.--.--,..,.,~,.:•...x..-.-_.......,., ___ ,. ____ ..,,.,_"-~""·--~•.w:"""'·•,_,...;-._,-,_.,-,,,,•_o~~~-.. _,..,.""'~"• ,.. * .., •• ._._.,,_,..,._, ___ ....,,..,.-.-. .,_,_._.""'_ 
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tor both ra.t and rabbit serum aJ.bumin. Both Keresztes-Na.gy (1971) and Bas-
sett (197.l) have estimated that MSA should have a molecu1a.r weight ..of approx-
In accordance with these estimates, a molecular weight of 
69,000 wa.s used in aJ.l caJ.cula.tions involving MSA. The ionic strength of the 
phosphate buffer was caJ.culated at 0.17 arbitrary \Ulits (Martin, 1962). The 
concentrations of HSA and MSA were 57.97 x io-5M (4%). Many investigator11.11 
among them McMena.my and Oncley (1958), Anton (1960-1961), Eichman ~ !!_ 
(1962), K\Ulen (1965), Conard~ !!:1, (1971) and Rudman~!!_ (1971), ha.ve not , 
ma.de d.a.ta. adjustments for Donnan equilibrium effects or the space occupied by 
proteins and other solutes (solute space); However, Keen (1966b) stressed 
that these corrections were necessary for data. accuracy. Therefore, it was 
decided to compare the number (n) and classes of binding sites and their 
association constants (K) prior to and after making the d.a.ta corrections dis-
cussed by Keen. 
The vaJ.ues utilized for the cha.ra.cteriza.tion of DPH binding sites and 
association constants for HSA are presented in Tables 2 and 3, while those 
for MSA are on Tables 4 a.nd 5. Examination of the tables reveaJ.s that MSA 
bound approximately 96-83% of the DPH present in the aJ.bumin retentate, com.-
pa.red to 85-74% for HSA, with increasing drug concentrations. This species 
difference in serum aJ.bumin binding ability is further emphasized by the fact 
that MSA bound 28-35% more DPH per mole of aJ.bumin (r) than HSA. Another 
striking difference in the binding of DPH by the two aJ.bumins is illustrated 
i in Figure -2. At low initiaJ. dnj.g concentrations, the moles of DPH bound per 
I
I mole of aJ.bumin for HSA and MSA are approxir.lately equal, resulting in compar-
able fractions of unbou."ld (free) DPH. However, as the initiaJ. DPH concentra-
[ I tions are increased, the concentrations of free drug in MSA pJ;"Otein compart-l "---------------~--6i:--~---------· -"·~·"··-'"·' 
tj -J."f''t1l'· 
r 
r 
r 
' 
ment become less than one-half' that observed with HSA. 
sca.tchard plots of diplienylhyd.a.ntoin binding site data. with HSA are il-
1ustrated in Figure 3 and 4; those with MSA a.re presented in Figure 5 and 6. 
!{a.rush (1950), Sca.tchard (1949, 1950), and others have reported that 'homo-
geneity of binding sites (a. single class} produces a. straight line plot. When 
the plotted points a.re extrapolated to the abscissa. and ordinate, the inter-
cepts equal. n and nK respectively {see Appendix). If a curved line is plotted 
from the r/c vs. r relationship, the binding sites a.re considered heterogenous 
(more than 1 class of sites}. 
The plots of these data produced curves; hence, it was assumed that more 
than one class of binding sites were responsible for binding DPH. Resolution 
of the curves into two asymptotes revealed that two classes of binding sites, 
n1 and n2, were available to DPH on both MSA and HSA. Table 6 contains the 
l I values caJ.culated for the albumin binding sites and their association constant~ 
Resolution of the HSA a.ndMSA curves provides data indicating that both 
albumins contain approximately 7-8 DPH binding sites. Each species of albumin 
appears to contain a. smaJJ. pr:!.ma.ry number of binding sites having high DPH 
affinity, as represented by K1 , and a much larger number of secondary sites 
with lesser affinity. Comparing n and K vaJ.ues, the HSA primary binding site 
class values a.re much smaller (0.03 - 0.04) than for MSA (0.6); however, the 
association constants for HSA (139,613 - 137,317) are approximately twice tha.~ 
of MSA. (56,o84 - 56,988). On the other hand, the number of secondary binding 
I sites for HSA ranged from 7.3 t0t7.9 and a.re slightly larger than for MSA 
' 
' 1 (6.9 - 7.4); but the MSA association constant is a.bout 65% greater (822-8o6 
! l vs. 1349-1348). 
~ i 
. t_~ ·-~,, FinaJ.ly, exnmin_:_~~~~ of T~~~. ~hat data. correction ~~~~; 
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produced by Donnan equilibrium effects and solute space apparently had little 
infJ.uence on the resuJ.ts. Nevertheless, a.ll resuJ.ts have been ~usted to 
reflect the effects of these parameters for accuracy. 
Figure 7 illustrates the effects of varying the DPH concentration upon 
the concentration of the unbound fraction (TabJ.es 3 and 5). As the concen .. 
tration of DPH in the albumin retentate doubles, the free drug concentr&tion 
approximately doubled. This rapid, large increase in free drug availability 
becomes more :i,mportant since this effect was achieved with only smaJ.l alter-
ations in the percent of DPH bound, Figure 8 shows that minor shifts in the 
percent of drug bound also resuJ.ted in a doubling of free DPH concentration. 
Thus, at serum concentrations considered most desirable therapeutically 
(10-20 mcg./ml. as represented by the aJ.bumin retentate fraction), only a 
small fraction of the drug was unbound. However, as DPH albumin fractions 
increased, the unbound fraction rapidly increased. By increasing the initial 
DPH concentration from 6.29 to 12.54 x io-5i.1, the drug concentration in the 
HSA retentate was equivalent to serum concentrations (30 mcg./ml.) measured 
when drug toxicity was observed in patients as reported by Buchthal ~ !:1_ 
(l96o) as well as Kutt and coworkers (1964). These aJ.terations occurred with 
only a Very slight reduction, from 83.3 - 81.6, in the percent of drug bound. 
The effects produced by pH alteration upon the concentration of unbound 
(free) diphenylhyda.ntoin in 4% HSA and MSA are shown in Figure 9, Tables 7 
and 8. Reduction of pH from 7.6 to 7.0 produced parallel linear increases in 
the unbound DPH ~ra~tio~ from 2~4 - 2:67 ~cg.~ml. (19.2~n with HSA, and 0.63- I 
0.97 mcg./rrll.. (54.0~o) with 1-!SA. When considering the moles of drug bound/mole! 
I 
of aJ.bu.-:i.in (r), the fraction of DPH bound decreased as the pH was reduced. · l 
Increasing the pH to 7.6 from 7.4 reveaJ.ed a decrease in the percent of free I 
_______ , _______ _,,,.._,,.,.._ . _ ~-~·------- _J 
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drug in HSA a.mounting to approxima.tel.y 12.6%. Decreasing the pH from.7.4 to 
7.0 increased the unbound fraction 3.0 - 6.63. In contra.st, increasing the 
pH from 7.4 decreased the free fraction in MSA 14% whi1e a reduction el.evated 
the unbound concentration from 16.3 - 34.9%. Thus, pH changes appeared to 
have little effect on unbound DPH in HSAwhereas a. reduction in pH appeared 
to significa.ntJ.y affect the unbound DPH concentration in MSA. Again, exaiiU,-
nation of the aJ.terations occurring in the percent of drug bound ·show that the 
changes discussed resuJ.t from onl.y a smaJ.1 deviation (2%) in the percent of 
DPH bound. 
AJ.terations in the binding of dipheny.l.hyda.ntoin as the resu1t of varying 
the concentration of aJ.bumin a.re presented in Figure 10 a.nd Tables 9 a.nd 10. 
As expected, an increase in aJ.bumin concentration was accompanied by a de- . 
crease in the free drug fraction a.nd a.n increased DPH concentration in the 
albumin retentate. The free drug concentration in HSA retenta.te decreased 
1 fror:i. 5.13 mcg./ru. in l~~ HSA to 1.67 mcg./ml. in 6j'a HSA. At a. 1% concentra-
tion of MSA, the unbound DPH fraction was 2. 74 mcg./ml. a.nd o. 74 mcg./ml. a.t 
4% MSA. ConverseJ.y, diphenyJ.hydantoin in the HSA (1-6%) retenta.te rose !rO$ 
12.26 - 16.28 and from 14.68 - 17.o8 in MSA (1-4%) respectiveJ.y. These find-
ings, however, were in contra.st to those where drug .concentrations were varied I 
and free drug concentration increased a.s the drug concentration in the ~umin 
retentate rose. In the aJ.bumin variation experiments, there was a reduction 
of 1lnbound (free) diphenylhydantoin of up to 67.4cj., in HSA and 73%in MSA even 
as the drug concentrations in ttte albun.in retentate rose. Therefore,. the 
moles of drug bound per mole of albumin (r) had to increase as a resuJ.t of 
elevated albumin concentration. The actuality of this phenomenon a.nd a com- ~ i 
effect in HSA and HSA are shown in Fj,gurell. 
l 
EXlllllination'. 
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of the data revealed that increasing the HSA concentrations from 1 to 4i pro-
duced a. 77-3% (0.0449-0.0796) increase in r, while increasing the HSA concen-
tration to 6% produced an overal.1 105% (0.0449-0.0919) increase in ~. Simi-
1ar1Y increasing MSA concentrations from 1-4% caused an overal.1 3~ (O.O"fl-
0.1028) increase in r. In al1 of the DPH-a.lbumin interaction experiments, MSA 
was found to bind more DPH than HSA. The moles of drug bound per mo1e of' MSA 
were almost twice that of HSA at l a.nd 2%, while at 4% a 29.1% differential. 
existed. Thus, it would appear that the number of binding sites unmasked per 
mole of aJ.bumin would be dependent upon albumin concentration, amount of drug 
present, and the total configuration of the albumin molecules at the time. 
The effect of liga.nd competition on the binding of diphenyllcyda.ntoin to 
huma.n serum albumin is presented in Figure 12, Tables ll and 12. When com-
pared to control values, the presence of phenobarbital ca.used some variation 
but had general1y little effect on the DPH-albumin complex or on the concen-
tration of free DPH. Warfarin, reported by O'Reilly (1967) to be bound to 
albumin 80 to 90%, appeared to cause a slight reduction in the unbound DPH 
concentration. When the warfarin pre-dialysis concentrations were increased, 
this influence was diminished. Similarly, the presence of trimethadione al.so 
produced a decrease in unbound DPH. However, in contrast to warfarin, increa.s 
ing the predialysis concentrations of trimethadione f'urther augmented the 
binding of DPH as compared to control values. The various changes observed 
in the unbound (free) DPH fraction due to the presence of phenobarbital, 
warfa.rin, and trimethadione occ1'!"red without influencing the concentrations 
of diphenylhydantoin in the albumin retentate fraction or unduly altering the 
colcs of drug bound per mole of albumin ratio. On the other hand, ad.di tion of j 
phenylbutazone, reported to be bound by albumin 95% (Anton, 1961), to the 
I 
I 
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d,ia.l.ysis system antagonized the binding of diphenylhyda.ntoin to HSA. When 
compared with control vaJ.ues, phenylbuta.zone appeared to inhibit the inter-
action between DPH and a.J.burnin, increasing the concentration of free diphenyl-
}lydantoin from approximately 6 to 49% (2.68 - 3.78 mcg./ml.). The aJ.teration 
in free DPH was apparently due to a reduction in the moles of DPH bound per 
mole of a.J.burnin {r). The presence of phenylbuta.zone decreased the r vaJ.~ 
between 2.5 and 20.2% (0.0776 - 0.0635) when compared to 0.0796 for the DPij 
control. 
. 
Experiments were conducted to determine whether diphenylhyd.a.ntoin serum 
and total. brain concentrations could be correlated with the protection afford~ ' 
ed against ma:xima.l electroshock (MES) convulsions in mice. Additional. MES 
experiments were designed in an attempt to relate indirectly and generaJ.ly '· 
the results obtained from the diphenylhyd.a.ntoin-mouse serum albumin binding 
experiments to alterations in pha.rmacologicaJ. activity of the drug by induc-
ing acidosis and a.1.kalosis in mice. Preliminary experiments revealed that 
jections of NH4Cl or NaHco3 to induce acidosis and a.J.kal.osis respectively, 
did not aJ.ter the incidence of tonic extensor seizures or appear to change the 
seizure pattern produced by MES when compared to controls. Table 13 shows 
that the i.p. median protective dose (PD50) for DPH against MES was 10.4 mg./ 
Kg. in normaJ. animaJ.s. In a.J.kal.otic mice, the PD50 was not aJ.tered, while 
.~-. 
acidosis appeared to indu~e an increased sensitivity to the drug. The PD50 
for diphenylhyd.a.ntoin in a.cidotic mice shifted from 10.4 rng./Kg. for the con-
trols to 8 .• 4 mg./Kg. This alte~tion in PD50 was statistically significant 
(P < .01). 
Table 14 toeether with Figures 13 and 14 compo.re diphenylhydantoin scrum 
1 and brain concentrations with the percentaee of animaJ.s protected by each DPH ! i 
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The percentage of mice protected against MES in a.ll experiments ap-
peared to be related to both serum and brain levels. a.s DPH concentrations in 
serum and brain rose, the percentage of an:iJna.J..s protected increased. When com-
pa.red with control an:iJna.J..s receiving comparable doses, i.e., 10 mg./Kg., the 
a.cidotic an:iJna.J..s had lower DPH serum concentrations (7.74 mcg./ml. vs. 8.43) 
but slightly higher brain concentrations (11.64 vs. 10.82 mcg./gm.). In asso-
ciation with this shi~ in drug concentrations, the a.cidotic mice were a.i'f'ord-
ed a higher degree of protection, 75.0C/o vs. 37.5%. On the other hand, the 
changes observed in the alkalotic mice were much less clearly defined. The 
diphenylhydantoin anti-MES protective dose 50% in normal mice was equal to 
that in a.J.kalotic mice. At 10 mg./Kg., the serum concentration in the alka-
lotic mice was higher (8. 58 vs. 8. 43 mcg. /ml.) and the brain concentration . 
lower (9,67 vs. 10.82) than in normals. Associated with this change was a 
decrease in the percentage of a.lkalotic animals protected. In contra.st, a.t 
12.5 mg./Kg. there were decreases in both serum (9,44 vs. 11.24) and brain 
(13,7 vs. 14.17 mcg./ml.) DPH concentrations of the a.J.kalotics when compared 
with the normals; but, 85.7% of the a.J.kalotic animals were protected while 
75% of the normals were protected. In general, the bra.in concentrations were 
lower in the aJ.kalotic mice while serum concentrations were mixed when com• 
pared to controls. This combination of differences in the a.J.kalotic mice 
appeared to produce a nixed MES antagonism pattern, resulting in. a PD50 
identical with that of the control animals. 
I 
i 
I 
. ! 
I 
' 
I 
I 
I 
I 
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TABLE I 
Ef'fect of Diphenylhyda.ntoin, NaHC03 or NH4Cl upon Blood pH 
of cn1 Strain Micea. 
Saline Diphenylhydantoin NaHC03 pH Control (12 mg./Kg.) (1 gm./Kg.) 
Average 7.39 7.41 7,55 
s. D. .. 0.04 0.04 o.o6 
s. E. 0.02 0.01 0.02 
Level of Significance 
vs. Controls N. s. P< 0.001 
Level of Sicnificance 
vs. DPH treated P< 0.001 
a.seven mice were used per group. 
NH4Cl 
(400 mg./Kg.) 
7,23 
0.02 
o.oo 
P< 0.001 
P< 0.001 
A., ) 4 Q 
.•t Ji$! L :..: lid . L ,ZJ414! JUJU jfaj~ 
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1 TABLE 2 
8nata not corrected for Donnan equilibrium effect or space occupied by solutes. 
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I TABLE 3 
Diphenylhydentoin Binding Site Data With RSA (Corrected)8 
l i--- ~~-~----------~-----..._ _______________________________ __. 
r 
f•,_,....,_, -C.i.c.·~-·;.,.-~,..._.~_.,,._-..,.,,...,,,.._.,"" 
"" I TABLE 4 ~ 
I Dipbeny1~dantoin Binding Site Data With MSA {Uncorrected)a I 
l Drug Concentration Final Free Moles Moles Drug I Initial Dr~ in Albumin Reten:3 Drug Co~c. (c) Drug Bo!P;d % Drug Bound/Moles r/c i Cone. (10- M) tate (Moles x 10 ) (lO- M) (x 10- ) Bound MSA (r) (x 103) 
J.4.59 0.1229 14.oo 95.96 0.0503 40.927 I 3.J.6 
' I 6.29 28.90 0.2667 27.62 95,57 0.0992 37,195 
. I 
l2.54 57,26 0.6083 54,34 94.90 0.1953 32.106 
.. 
25.04 ll3.32 1.4312 106.45 93,94 0.3826 26.733 
-..j I 50.04 22l.56 3.8812 202.93 91.59 0.7293 18.790 ~I 
l00.05 428.72 10.7333 377.20 87,98 1.3556 12.630 I 
125.09 529.63 14.7188 458.98 86.66 1.6495 ll.207 
200.o4 822.22 28.6646 684.63 83.27 2.4600 8.582 
a Data not corrected for Donnan equilibrium effect and space occupied by solutes. 
r-.... --,··-··--~·-
l 
• 
TABLE 5 
Diphenylhydantoin Binding Site Data With MSA (Corrected)a 
Drug Concentration Final Free Moles Moles Drug 
I Initial Dr~ In Albumin Reten-8 Drug Cone. (c) Drug B§und %Drug Bound/Moles ! Cone. (10- M) tate (Moles x 10- ) (10-5M) (x 10- ) Bound MSA (r) I 3.16 15.10 (8.62)b 0.1246 (0.34)b 14.50 96.o4 0.0521 
I 
i 
I 
6.29 29.91 (17.08) 0.2708 (0.74) 28.61 95.65 0.1028 
t 12.54 
.. 59.26 (33.85) o. 6167 (1.69) 56.30 95.00 0.2023 
I 
I I 25.o4 117.29 (67.00) 1.4500 (3.97) 110~33 94.o6 0.3965 i\5 I 
I ' 50.04 229.31 (130.99) 3,9312 (10.78) 210.44 0.7563 I 91.77 
I 100.05 443.72 (253.47) 10.8750 (29.81) 391.52 88.24 l.4070 
I 125.09 548.17 (313.10) 14.9125 (43.61) 476.59 86.94 1.7128 200.04 851.02 (486.14) 29.0400 (72.59) 711.61 83.62 2.5570 
I 
I 
a . 
Data corrected for Donnan equilibrium effect and space occupied by solutes. 
bvalues in parenthesis represent DPH concentrations in mcg./ml. 
r/c (x 103) 
41.814 
37.962 
32.8o4 
27.345 
19.238 
12.938 
11.486 
8.805 
L-.-------~·----------------
TABLE 6 
Values Determined for the Number of Diphenylhydantoin Binding Sites (n) 
per Molecule HSA and ~IBA, and Their Association Constants {K) 
Human Serum Albumin (HSA) Mouse Serum Albumin (MSA) 
-Uncorrecteda - - Correctedb - - Uncorrecteda - -Correctedb -
Sites n nK K n nK K n nK K n nK K 
1 I Pr imary 
I I s econdary 
0.03 4188.4 139,613 o.o4 5492.7 137,317 o.6 33,650.6 56,o84 o.6 34,192.8 56,988 
.. 
7.30 6000.0 806 6.9 9,307.4 1,349 7.4 9,978.2 1,348 
7.5 42,958.0 
-.:i IT VJ otals i 7.33 10189.0 7. 94 ll861. 7 8.0 44,171.0 
I 
I 
! 
~ 
a Values were ~ corrected for Donnan effect or space occupied by solutes. 
b Values ~ corrected for Donnan effect and space occupied by solutes. 
TABLE 7 
Effect of pH on the Binding of Diphenylbydantoin to HSAa 
Drug Cone. in Cone. Free 
HSA Retentate Drug {c) i Drug Moles~ Bound/· 
pH (mcg./ml.) (mcg./ml.) Bound Moles HSA (r) 
-
7.6 15.48 2.24 85.53 o.o833 
7.4 15.18 2.53 83.33 0.0796 
7.2 15.10 2.59 82.85 0.0785 
7.0 15.o6 2.67 82.27 0.0780 
TABLE 8 
Effect of pH on the Binding of Diphenylbydantoin to MSAa 
Drug Cone. in Cone. Free Moles D~ Bound/ 
MSA Retenta.te Drug {c) 3 Drug Moles MSA (r) 
pH {neg. /ml. ) (mcg./ml.) Bound 
7,6 17.18 0.63 96,33 0.1041 
7.4 l7.o8 0.74 95.69 0.1028 
7.2 16.94 0.85 94.98 0.1013 
7,0 16.84 0.97 94.24 0.0999 
a A molecular weic;ht of 69,000 was used for hu.>r.an serur.i albumin (HSA) and 
for i:ouse seru.>r. albu.':1in (;;;.;A) 
b The albu."'.'.in concentration was 4~ and the initial DPH concentration of 
: .....~.···-~ ::.::=~.~~·--.. ·--·---·--·-~--~------ , . ., __ j 
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TABLE 9 
Effect of Protein Concentration (HSA) on the Bonding of Diphenylhydantoina 
Drug Cone. Cone. Free Drug (c) °/o Drug 
HSA Compartment HSA Compartment Bound Moles Drug Boun~ 
(mcg./ml.) (mcg./ml.) per Mole HSA (r) ·. 
l 12.26 5.13 58.16 o.o449 
2 13.76 3.68 73.25 0.0634 
4 (Normal) 15.18 2.53 83.33 0.0796 
6 16.28 1.67 89.74 0.0919 
TABLE 10 
Effect of Protein Concentration (MSA) on the Binding of Diphenylhydantoina 
Drug Cone. Cone. Free Drug (c) 
c/o MSA MSA Compartment MSA Compartment °lo Drug Moles Drug Bo'1!1d 
Cone. (mcg./ml.) (mcg./ml.) Bo'1!1d per Mole MSA (r)b 
l 14.68 2.74 81.34 0.0751 
2 16.07 1.44 91.o4 0.0921 
4 (Normal) 17.08 0.74 95.69 0.1028 
a The pH was 7.4 and the initill DPH Concentration was 6.29 x 10-5M 
b A molecular weight of 69,000 was used for the serum albumin 
a The HSA concentration was 4~, the pH 7.4, and the initial DPH concentration 6.29 X 10-5}(. 
:-.,,~·-,,-----------------------------------------------­
' 
' i 
I 
I 
I 
I Ligand j Concentration (10-5M) 
I I 
DPH Control 
DPH + Phenylbutazone 
25.0 .. 
50.0 
100.0 
200.0 ::i I 
1 j DPH + Warfarin Na 
1.60 
3.12 
6.25 
12.50 
TABLE 12 
Effect of Ligand Competition on the Binding 
of Diphenylhydantoina 
DPH Cone. Cone. Free DPH 
HSA Compartment HSA Compartment %DPH 
(mcg.Lml.) (mcg;. [ml.) Bound 
15.18 2.53 83.33 
15.02 2 .• 68 82.16 
14.96 2.74 81.68 
14.25 3.41 76.07 
13.87 3,78 72.75 
15.41 2.32 84.94 
15.33 2.39 84.41 
15.33 2.39 84.41 
15.31 2.42 84.19 
Moles Drug 
Bound/ 
Mole HSA 
O.CY796 
0.0776 
0.0768 
0.0682 
o.o635 
o.o823 
o.o814 
o.o814 
o.oau 
'lo Change of 
Free DPH 
From Control 
5,93 
8.30 
34.80 
49.41 
-8.30 
-5.53 
-5.53 
-4.35 
a The HSA concentration was 4'f,, the pH 7 .4, and the initial DPH concentration 6.29 X lQ~·. 
' ~; ' 
! 
TABLE 13 
Brain and Serum Concentrations of Diphenylhydantoin in Normal, 
Acidotic and Alkalotic Mice Following Convulsions Induced by MESa 
Diphenylhydantoin 
Dose (mcg./Kg.) Normal Acidotic Alkalotic 
6.4 1/8 
8.0 1/8 3/8 2/8 
10.0 3/8 6/8 2/8 
12.5 6/8 6/7 
15.6 8/8 
Calculated Median 
Protective Doses 
±9%, Confidence 
Limits (mg./Kg.) 10.4 ±1.6 8.4 ±1.2c 10.4 ±1.6 
a MES, ma.xima.1 electroshock (50 ma. -0. 2 sec. duration), was administered one 
hour a~er i.p. injection of DPH. NH4Cl (400 mg./kg.) or NaHC03 (1 grn./kg.) was injected i.p. 45 min. prior to MES to induce acidosis of 
alkalosis. 
b Fraction indicates number of mice protected/ total number of mice. 
c Value significantly altered {P ( .01) when compared with normal controls. 
I 
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TABLE 14 
Diphenylhydantoin Antagonism of Maximal 
Electroshock Seizures in Normal, Acidotic, and Alkalotic Micea 
I Diphenyl-j hydantoin 
! (mg./Kg.) 
-------
"lo Pro-
tected 
Normals --------
Brain Serum 
mcg.Lgm. mcg.Lml. 
------- Acidotic -------- ------ Alkalotic --------
ofo Pro- Brain Serum "/oPro- Brain Serum 
tected mcs.·Lgm.. mcg.Lml. tected mcs.·Lgm.. mcs_.Lml. 
:, 
6.4 
8.0 
10.0 
12.5 
15.6 
.. 12.5 
37.5 
75.0 
100.0 
12.5 
8.45 ±0.09 7.58 37.5 
10.82 ±0.17 8.43 75.0 
14.17 ±0.20 11.24 
17.22 ±0.31 13.91 
7.33 ±0.16 5.o6 ------
8.83 ±0.18 6.62 25.0 8.83 ±0.24 9.05 
b 11.64 ±0~11 7.74 25.0 b 9.67 ±0.30 8.58 
-------
85.7 i2.70 ±o.2ob 9.44 
------- .:.-----
a MES, rna.xima.1. electroshock (50 ma-0.2 sec. duration), was administered one hour after i.p. injection of 
DPH. NH4c1 (400 mg./kg.) or NaHC03 (1 gm../kg.) was injected i.p. 45 min. prior to MES to induce 
acidosis or alka.1.osis. Brain concentrations are given in mcg./gm, wet tissue ± standard error. 
b When compared with controls, P ( O. 01. 
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CHAPTER V 
DISCUSSION 
The responses of living systems to drugs vary widely, especially in the 
area of therapeutics. Much of this species specific, intra-species and intra-
individual drug-response variation may be attributed to the biochemical., phy-
siological, and pathological conditions which prevail during drug adminis-
tration. The involvement of serum albumin in drug-response variation was 
clinically documented when Sellers and Koch-Weser (1970) demonstrated that a 
metabolite of chloral hydrate displaced albumin bound warfa:rin to an extent 
which produced a potentiation in the hypoprothrombinemic effect of wa:rfarin. 
The serum protein-bound fraction of a drug is considered inactive until re-
leased. Thus, the binding of drugs by serum albumin may share in drug int~r-
actions, alter biotransformation and/or excretory rates, thereby modif'ying the 
therapeutic effectiveness o~ a drug. Once the binding protein becomes sat-
urated, or if competition between drugs or their metabolites for serum albumin 
binding sites becomes excessive, an increase in side effects or toxicity may 
appear, especially if drug administration is continued. Sustained therapy, in 
contrast, may be the result of prolonged blood levels due to the slow release 
of drugs from the drug-albumin complex.(Storm van Leeuwen, 1924; Davis, 1942; 
Goldstein, 1949; Taylor, 1954; Anton, 1960; Keen, 1966a,b; GOth, 1966; Meyer 
and Guttman, 1968). The relationship between drug-serum albumin binding, pH, 
albumin concentrations, and drug concentrations with effectiveness has been 
l ! discussed.and examined by Goldstfin, 1949; Goldbaum and Smith, 1954; Waddell 
l l and Butler, 1957; ·and Brmme, 1969. These investigators demonstrated that the 
I 
' I response of an orGanism to druGs may also be influenced by alterations in ser-
j ur.1 pH or albu.1Jlin content which may result from changes in the milieu interieur 
l 
-93-
of an organism. Thus, any physiological, biochemical, or pathologicei con-
dition which might alter the drug-serum albumin complex might modify the 
pharmacological effects of a drug, especially if the drug is highly bound by 
serum proteins. 
Diphenylhydantoin in anticonvulsant doses acts principally on the motor 
cortex, inhibiting the cortical spread of seizure activity (Toman, 1965). The 
drug acts to reduce the post tetanic potentiation of synaptic transmission 
within the spinal cord, thereby interfering with the development of high fre-
quency transmission of impulses in the cerebral excitatory feedback circuits. 
The high intensity of these feedback circuits apparently results in grand mal 
seizures. Toman indicates that DPH appears to stabilize excitable membranes 
and this activity is apparently accompanied by a reduction of intracellular 
sodium. Goldstein (1949) has emphasized that the free unbound form of the 
drug is responsible for the pharmacological effects of drugs. Thus, before 
DPH can· exert its anticonvulsant action, an adequate quantity of the drug in 
its unbound form must be available to interact with receptor sites. 
The work by Lightfoot and Christian (1966), Loeser (1961), Conard ~ al 
(1970), and Rudman et al (197la, b) demonstrated that diphenylhydantoin is 
bound to a great extent by serum albumin. Conard indicated that 90-95% of the 
DPH in huma..'1. serum was bound by serum proteins. The present work is in agree-
ment since approximately 74-85'~ of the DPH present in the protein retentate 
chamber was bound to human serum albumin. 
Prior investigators have d~cument·ed the binding of DPH to serum proteins 
and albumin. However, they failed to determine binding sites. In this work, 
binding sites and association constants on both human serum albumin (HSA) and 
; raouse serwn albur.1in (MSA) have been characterized. Although restricted to 
4 
using only low concentrations of DPH, because of their dialysis system, Rudman 
and associates (1971 a,b) did make a Scatchard plot of their results.- Since 
the information was limited, Rudman did not attempt to characterize DPH 
binding sites; however, their information was sufficient to determine an nK 
They determined that the human serum albumin nK was 11,000 'for di-
phenylhydantoin. Their nK value :for HSA confirms the nK values of 10,189 
(uncorrected) and 11,861.7 {corrected), obtained during this research. 
Examination of the Scatchard plots suggests that the secondary group of 
binding sites may play a greater role in the binding o:f DPH by H$A that MSA. 
The apparent contribution of the primary and secondary binding site groups to 
the total a.mount of drug bound has been estimated using the following equation 
(Mais, 1971): 
FB = Fl + F2 = Pc (n1K1) 
T (1 + IS_c) 
+ Pc {n2K2) 
T (l + K2c) 
(1) 
where FB is the totaJ. fraction bound; Fi represents the fraction bound by the 
primary group of sites and may be substituted by Pc (nJK1) ; F2 represents 
T (l + K1 c) .. 
the fraction bound by the secondary group of sites and may be substituted by 
Pc (n2 K2) ; P is the protein concentration; T equals the a:.nount of drug bound 
T (l + K2c) 
plus c; K is the association constant; and c represents the concentration of 
free or unbound drug. Using this formula, it was determined that DPH was 
mostly bound by the secondary sites on HSA. At concentrations in the a.l.bumin 
' ! retentate chamber corresponding,to sertu71 values reported as therapeutic in 
' i 
i j 
~ 
' 
humans, the seconda:cy group of sites accounted for approximately 72% o:f the 
D:t'H bound. Lnubsher (1966) reported a scrum level of 94 mcg./rnl.. just prior 
~o the death of a child. Buchthal et al (1960) and Kutt and associates (1964) l ~----------------9-5 ________________ _, 
related the eA-tent of toxic symptomology in epileptic patients with DPH serum 
levels. When concentrations equivalent to those causing toxicity were repro-
duced in the albumin retentate chamber, the secondary group of binding sites 
was responsible for binding up to 81% of the DPH bound. When the DPH }>resent 
in the protein retentate chambers was comparable to concentrations reported 
at death, the secondary sites accounted for approximately 94% of the drug 
bound. Thus , it appears that the secondary group of binding sites are ex-
tremely important in the binding of DPH to human serum albumin. This assump-
tion is in agreement with finding reported by Oester ~ al (1971) for the 
binding of warfarin. While examining the effect of salicylates on warfarin 
binding by HSA, they reported that the secondary group of binding sites played 
an important role in the binding of warfarin. They also indicated that the 
secondary group of binding sites might play an important role in displace-
ment reactions. 
In contrast, the secondary group of binding sites only accounted for ap-
proximately 25% of the DPH bound when the albumin retentate chamber contained 
MSA concentrations equivalent to that determined in the serum of mice which 
were completely protected against tonic convulsions induced by electroshock. 
However, the role of the secondary group of sites became increasingly impor-
tant as drug concentrations were increased. When albumin retentate chamber 
concentrations were equivalent to those approximately sub-lethal levels 
(67 mcg./w..1.), the secondary group of sites accounted for approximately 34.4% 
! of the drug bound. ffnen the D?!\ concentration in the protein retentate char.'l-
1 ber was increased to 253 ncg./ml., the secondary group of sites was respon-
l sible for approximately 65'.-~ of the drug bound. Therefore, it would ap:penr l that the secondary group of binding s.:.tes on MSA might play a major role in 
~~~~~~~~~--~--~~~~~~~--~~------------------------~~.___. 
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the binding of diphenylhydantoin if drug serum concentrations exceeded ther-
apeutic levels. 
When discussing the number of binding sites per group, the following 
question has often been expressed: how can there be a fractional number of 
binding sites, such as ammonium or carboxyl ion groups, be present on a mole-
cule of albumin? The results obtained via the Scatchard plot are in act-
uality an average, calculated through statistical computation. Thus, if a 
small n1 , such as that calculated for DPH with HSA (0.04) is obtained, then 
theoretically the steric conformation of the protein nolecules may restrict 
the binding of DPH. In the situation when n1 = 0.04, four binding sites out 
of one hundred molecules may be available to DPH. This explaniation is 
strengthened by the fact that as the concentrations of diphenylhydantoin ~ere 
increased, a smaller proportion of the drug was bound per mole of albumin, at 
a given protein concentration. Thj.s suggests that the molecular configura-
tion of the drug-protein complex has become more intricate, exposing fewer 
binding sites. Thus, as the drug concentration was increased, binding site 
saturation also increased while the fraction of undissociated DPH rapidly 
increased. 
To date, little investigation has been given to the possible ef't'ects of 
albumin variation on binding of drugs. It has become the custom to charac-
terize the binding sites and association constants of a drug, using low con-
centrations of albumin, 1% or less. Goldbaum and Smith (1954), Zaroslinski 
et al (1969) and Browne (1969) i1ave demonstrated that the moles of drug bound l 
I 
I 
' 
per mole of albumin (r) are increased as the concentration of albumin was 
· increased The work presented here provided additional evidence concerning I thi• effe~t. 
'•··--------------------·------------~--. 
The r.-1oles of drug bound per mole of albumin were observed to 
-97-
shi~ from 0.0449 to 0.0919 when concentrations of HSA were increased from 
1 to 6%. A similar pattern was seen when MSA albumin concentrations were 
increased from 1 to 4%. However, the r/c ratios were not increased propor-
tionally, 2400 to 15,056 for HSA and 7527 to 37,962 for MSA respectively. 
Thus, if a Scatchard r/c vs. r plot would ?e made, these points woul,.d shi~ 
drastically upward and to the right. It he.s been suggested that drugs may 
increase the number of available binding sites by changing the molecular 
conformation of the protein (Markus and Karush, 1958; McMenamy, 1963, Keen, 
1966a). Assuming a continuation in the r/c shifts at a given albumin con-
centration, using varied drug concentrations, it would appear that the number 
of binding sites, their association constants and concentration of unbound 
drug might easily be altered if a change does occur in the albumin concen-
tration. 
Black (1970) furnished information showing that the albumin concentra-
tion in the serum of Charles River strain mice ranged from 3.76 to 5.06%, 
depending upon the age and sex of the animal. Bernstein (1966) reported that 
the serum protein content in 15 strains of mice ranged from 3.99 - 6.833. 
He also showed that the serum albumin concentration in three strains of these 
mice ranged from 2.17 to 3.38%. One of the strains had an intra-strain dif-
ference ranging from 2.17 to 3.153. In 1966, Mills reviewed the literature 
concerning circadian rhythms in man. He mentions that Forsgren (1935) re-
ported that albumin concentrations in rodents were subject to circadian 
rhythms. Frankel (1963) reported that the concentration of albumin in the 
' 
serum of normal humans ran6ed from 3.5 to 5.6'j~. The work reported by Bose 
et al (1960) adds an additional complication to the DPH-albumin binding 
I picture. T'hey de:nonstrated that oral administration of 10 mg./Kg. DPH to 
~.·.· .. L __ _ l -96-
rabbits resulted in a reduction of serum albumin content 19% in acute exper-
iments. They also determined that the chronic administration of lOmcg./Kg. 
DPH resulted in a maximal reduction of serum albumin amounting to 28~. The 
peak effect occurred within eight days and values returned to normal by the 
fifth day after discontinuing the drug. These variations in the concentra-
tion of albumin in serum attain greater significance when recalling that in 
vitro studies demonstrated that decreases of less than 2% (83.3 - 81.6) in 
the percentage of albumin bound DPH could possibly double the concentration 
(15.2 - 29.8 mcg./ml.) of pharmacologically active DPH in the serum. More-
over, the concentration of albumin as well as the type of buffer system em-
ployed may also partially account for differences in binding sites and asso-
elation constants obtained for the same <h'.ug by separate investigators. 
Administration of drugs such as puromycin affect the metabolism of amino 
acids necessary for the anabolism of serum albumin by interfering with pro-
tein synthesis at the assembly state on the ribosome. Physiological condi-
tions such as renal impairment, liver disease, malnutrition and dehydration 
may produce variations in serum albumin. Odar-Cederlof et al (1970) reported 
--
that epileptic seizures in a uremic patient were.controlled by DPH at plasma 
concentration of less than 2 mcg./ml. They found that the capacity of the 
plasma proteins to bind DPH was greatly reduced. Reidenberg and coworkers 
(1971) found a significant correlation between unbound DPH and azotemia, and 
suggested that the low binding of DPH in uremia was due to a qualitative 
change in the drug-bindin0 proteins. · They indicated that uremic patients 
' 
would most likely respond favorably to DPH at low plasma concentrations and 
experience toxicity at serum levels ordinarily considered non-toxic. Reiden-
berg concluded: "The alteration of drug binding by pathologic states should 
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be considered when values of total plasma concentrations of protein-bound 
drugs are used to establish or modify drug dosage regimens." 
Therefore, not only drugs and abnormal. disease states but the normal 
everyday biochemical reactions within an individual can and do produce wide 
fluctuations of serum albumin. The data summarized indicate that changes in 
serum albumin concentrations may be a participating factor in the regulation 
of the diphenylhydantoin dose-response relationship. The serum concentration 
of albumin controls the number of molecules present for binding DPH, thereby 
regulating the concentrations of unbound drug available for pharmacological. 
activity. 
As with albumin, little work has been published discussing the effects 
of hydrogen ion variation, within physiological. limits, upon the binding of 
drugs by serum proteins. In the ~vitro MSA experiments, decreasing the pH 
from 7.4 to 7.2 produced a 16% increase in the concentration of free DPH; a 
reduction in pH from 7.4 to 7.0 increased unbound DPH 35%. When the pH was 
increased from 7.4 to 7.6, the unbound DPH concentration was reduced by 14%. 
In an effort to determine whether the in vitro alterations in DPH binding 
might, with changes in pH, be reflected in ~' normal, acidotic, and al-
kal.otic mice, treated with DPH, were subjected to maximal electroshock (MES). 
The administration of NH4c1 reduced in vivo blood pH to approximately 7.23. 
Induction of acidosis shifted the diphenylhydantoin PD50 against tonic con-
I :·:::::::i:: ::s!T:::31:~,:<:·i:•~:::oo:::o •:;~.:::~ I 7. 5 5. Thi• illdllction of ill-.al~•is, however, did not alter the PD50 when com-
! pared to normal mice. In the in vitro HSA experiments, reducing the pH from 
l_7_._4_t_o_7_._o_p_r_od_u_c_e_d_o_1_11_y_a_6_._6_~i-c_h_an--ge~~i-·n_t_1_1e_c_o_n_c_e_n_t_r_a_t_i_on_o_f_un_b_o_un_d_D_P_H_._...a 
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I 
However, reducing the pH from 7.6 to 7.0 did cause a.n overall increase in 
free DPH approximating 19%. 
The results concerning the alterations in DPH-MSA binding and the~ 
~ anti-MES effectiveness of the DPH due to pH changes are consistent with 
work done by Goldbaum and Smith (1954) and.Waddell and Butler (1957). 
Goldbaum and Smith reported that the binding of phenobarbital and other bar-
biturates was "related to pH" and that maximal binding occurred at :PH 7 .8. 
Waddell and Butler demonstrated that the anesthetic dose 50% for phenobar-
bital was shifted from 158 ±3 mg./Kg. in mice treated with NaHC03. Treatment 
of the mice raised the blood pH 0.2 units when compared to normals. 
It could be argued that NH4Cl competed with DPH for albumin binding 
sites or altered the electro-shock pattern. The affinity for DPH as deter-
mined by the association constants (K) was approximately 65% greater for MSA 
than for HSA. If binding site competition is involved, one would have ex-
pected the HSA retentate to contain a concentration of unbound DPH comparable 
to that found in the MSA retentate. Had NaHC03 been in competition with DPH 
for serum albumin binding sites, the dosage of DPH necessary to provide pro-
tection should have been reduced. Preliminary experiments demonstrated that 
the administration of NH4Cl or NaHco3 failted to alter the incidence of tonic 
extensor seizures or overtly change the MES seizure pattern. These results 
were consistent with those reported by Hendley et ~ (1948) who reported that 
mild metabolic acidosis and alkalosis, induced by NH4Cl and Na.Hco3 respective-
ly, had no effect on the elect.i-o-shock seizure threshold in rats. They dem-
onstrated that severe netabolic acidosis caused an increase of 14% in elec-
' tro-shock threshold. I 
I 
Finally, Hendley reported that severe metabolic acid-
I osis or al.l{alosis had no effect "upon the maximal seizure pattern of rats, or 
.. ~ ...... ,,_,..,_-,,...---·-------------·------------------
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upon the resting electroencephalogram, the subconvu1sive Metrazol EEG dis-
charge and the threshold for evoked cortical potentials in rabbits".· Hence, 
it would appear that the increased effectiveness of DPH might be due to the 
physiological condition of acidosis and/or displacement through drug binding 
site competition and not to alterations in the MES seizure pattern. Although 
it is apparent that blood pH changes in the mouse may alter the effectiveness 
of DPH, the significance of hydrogen ion changes clinically would appear to 
be more dependent upon the overall condition of the patient at the time of 
drug administration. 
The binding of an anionic drug molecule by serum albumin may be attri-
. 
buted to the accessibility of the reactive prototropic groups on the protein. 
Therefore, the prototropic groups of the amino acids on the albumin mole~e 
should provide the best DPH binding sites. Steinhardt and Beychok (1964) 
have reported that the histidine-imidazole, lysine ((--amino) side chain, a.?Xl 
the arginine-guanidyl groups appear to be the active sites available for an-
ionic binding. 
The negative log of the dissociation constant (pKa) for diphenylhydan-
toin, a weak acid, is 8.31 (Sunshine, 1969). White and associates (1964) 
have listed the pKa for the histidine-imidazole group as 5.6 - 7.0, the 
lysine.+ amino as 9.4 - 10.6, and the guanidyl group of arglnine as 11.6 -
12.6. Examination of the pK values of drugs and amino acids, as well as the 
, I pH of the solvent system, allows one to estimate the extent of drug and amino 
t I acid ionization. This informa~on, in turn, provides a basis for conjecture 
r. 11 I . 
l
l The extent of ionization may be determined by substitution in the following 
equations: 
concerning the prototropic groups responsible for binding diphenylhyda.~toin. 
....,.__ . ...._ 
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HA ~ H+ + A- protein, Protein+ A-
H+ + 
~~==--RNH3 
pKw = 14 = pKa + pKb 
(Salt) 
pH = pKa + log (Acid) 
(1) 
(2) 
(3} 
(4) 
HA represents a wea.k acid a.nd R=~ the protein with -~ the prototropic 
group. 
As the hydrogen ion concentration in a solution containing diphenyllly-
dantoin is increased, the amount of drug ionized is decreased {equation 1). 
Therefore, the anionic form of the DPH molecule becomes less available for 
. 
binding as the pH is decreased from pH 7.6 to 7.0. In contrast, decreasing 
the pH from 7.6 to 7.0 increases the positive charge on the arginine, lys~ne 
and histidine prototropic groups (equations 2 and 4). A decrease in the 
amount of anionic charged DPH molecules in the albumin solution results in 
an increase in the free, undissociated drug available for pharmacological 
a.cti vi ty. At a pH 7. 4, the albumin molecule contains many more ionized 
lysine-(- amino and the a.rginine-guanido groups than histidine imidazole 
groups. Therefore, these two basic amino acids provide the most likely can-
dida.tes responsible for binding DPH. 
Assuming that lysine and arginine are the principal sites on the albumin 
molecule responsible for binding DPH, the chemical interaction at pH 7.0 to 
7.6 may be described as follows: 
H 
Ct.HsQN""-
-o 
Cf!s ( 
0-N 
H 
Diphenylhyd.a.ntoin (DFH) DPH 
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DPlC 
+ + Albwrl.n 
A canpa.rison of the amino acid composition of human sermn albumin reveal 
that the protein contains 12.3°/o lysine and 6.15% arginine (Phelps a.nd Putnam, 
196o). ~s suggests that the a.rginine-gua.nido groups mtzy ccmprise the pri-
mary group of binding sites on serum albumin, and lysine the secondary. How-
ever, the steric conf'o:rma.tion of the molecule ma:y also dictate the extent to 
'Which DPH is bound to ea.ch prototropic group. 
nie addition of phenobarbital, warfarin, and trimethadione, using pre-
dialysis concentrations up to 12.5, 50.0 and 4oo x 10-5M respectively, had 
little effect on the binding of diphenylhydantoin. In contrast, the addition 
of phenylbutazone in pre-dialysis concentrations, ranging fran 25 to 200 x 
l0-5M, increased unbound
1 
DPH up to 50%. 
When alterations in drug activity occur in the presence of other agents, 
it is tempting to attribute the change to enzyme induction~ Conney~ al 
(15)6o), Cucinell et al (1962), a.swell as Kato and Chiesara (1962) have demon-
strated that animals pretreated with phenobarbital and pentoba.rbital, as well 
as severaJ. other centrally actine com:pounds, are capable of inducing enzymes 
. ' j which metabolize drut;s in the liver microsO!!les. This enzyme induction has 
i led to the diminished pharmacolo.<jicaJ. activity of diphenylhydantoin, several 
i 
I 
'--·-------· 
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barbiturates, warfarin, tubocurarine, chlorproma.zine, etc. On the other hand, 
the work of Sellers a.nd Koch-Weser (1971) cautions against assuming that a 
decrease in drug activity is due to enzyme induction in the absence of enzyme 
da.ta. Protein binding experiments which show an absence of binding site dis-
placement should preclude the hypothesis that alterations in drug-serum pro-
tein binding are responsible for changes in pharmacological activity. Oester 
tl ~ (1971) showed that pentobarbital at concentrations less than 5 x 10""\t 
failed to produce axry appreciabl.e displacement of warfa.rin from binding s1 tes 
on HSA. The phenobarbital, DPH-HSA interaction experiments conducted in this 
study revealed that phenobarbital did not appreciably alter DPH binding. 
These results might have been anticipated since DPH is bound to HSA approx!-
mately 8~ while phenobarbital is bound approximately 5~. Thus, the experi-
ments reported in this work add further value to the theory, that in ~ 
diminution of DPH and wa.rfa.rin activity in the presence of pentoba.rbita.l. and 
phenobarbital is due, by excl.usion, to induction of drug metabolizing enzymes. 
In 1965, Yu~·~ reported that pretreatment of mice and rats with tri-
methadione decreased pentobarbi tal sleeping time and increased the rate of 
pentoba.rbital disappearance. They indicated that these changes in pentoba.r-
bital activity were due to enzyme induction of metabolizing enzymes. · There 
a.re no studies known to this author which indicate that tri!nethadione at con-
I centrations reported as therapeutic produces any reduction in the pharmacolog-
1 
ical action of DPH. If the pharmacological activity of DPH were to be de-
creased during conco:nitant a~~nistration with trimethadione, then the tri-
methadione-DPH interaction results with HSA in this work would tend to support 
a., enzyme induction theory. 
The drug interaction experiments with wa.rfarin produced unexpected 
::,_.,,,., ... __. ______________ ~--------------------.i 
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results. Drugs "1hich are highly bound to serum albumin, such a.s phenylbuta-
zone, warfarin, and salicylate, have of'ten been found to compete Yith and dis-
place other ligands from binding sites (Anton, 196o, Zarosllnski !!, al, 1971, 
and Oester and co-workers, 1971). O'Reilly (1967) reported that 80-~ of _the 
wa.rfarin present in the protein retentate wa.s bound to RSA. Thus, the extent 
to "1hich warfarin and DPH were bound to HSA a.re comparable. This lack of 
competition by warfarin for DPH binding sites on RSA mey be attributed to the 
roles pleyed by the binding site groups on the albumin molecule and the ca.pa-
ci ty of each drug to alter the molecular configuration of the protein. 
Oester !!, !:!_ (1971) demonstrated that although the secondary group of binding 
sites on HSA became more important to the binding of wa.rfarin as the drug con-
centrations were increased, the primary group of binding sites still contin-
ued to be daninant. Keen {1966b) has indicated that the affinity of an antag-
onist for albumin might "vary according to the drug with "1hich it was canpet-
ing because the antagonist's affinity would depend on its ability to distort 
the albumin molecule in the presence of the other drug". 
Phenylbutazone has been reported to displace a host of drugs f'rom serum 
albumin binding sites. Among some of the drugs displaced were suli'onamid.es, 
oral anticoagulants, phenoxymethylpenicillin, 1-tryptophan, and phenol. red 
{McArthur et !!.' 1971; McQueen, 19'59; Anton, 1960; .Aggeler ·~ !!' 1967; and 
Keen, 1966a) • As anticipated, phenylbutazone produced an aypreciable dis- . 
placement of DPH from RSA binding sites. Phenylbutazone has a pKa approxi-
mating 4.5 {Sunshine, 1969), and would be almost entirely ionized at a pH 7 .4., 
' I The dissociated. phenylbutazone should be very strongly attracted by the highlyJ 
char1;ed prototropic groups of arginine and lysine. Phenylbuta.zone is bound 
s.trong affinity of.· serum album:in_1l· 
~--------------·-------------------~--
approximately 95~ by HSA (l\nton, 1961). This 
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for phenylbutazone may partially account for the displacement of DPH. On the 
other hand, Anton, while studying the displacement of sulfonamides by phenyl-
butazone, phenylbutazone analogs, aminoPYTine, thiopental, probenecid, sura-
min, sa.licylate, etc., demonstrated that the pKa of a drug a.nd the percent 
that it is bound by albumin cannot be considered positive indicators of dis-
placement activity. 
However, he did indicate that a drug that was highly bound to albumin 
would have greater potential for displacement activity. Anton also reported 
that poly aromatic compounds such as phenylbutazone and DPH appeared to have 
a. more optimal displacement potentia.l. Since DPH is both highly bound and is 
poly aroma.tic, this might be a.n additional factor for the la.ck of competition 
by wa:rf'arin. On the other hand, phenylbutazone is bound to a. greater extent 
by HSA than DPH and is also poly aromatic which might account for the increase 
in unbound DPH in the presence of phenylbuta.zone. Anton demonstrated that 
only the drugs interfering with sulfonamide binding in vitro were a.cti ve !!!, 
~and showed that the extent of displacement !!!, Y!Y2, followed the relative 
order observed in vitro. Therefore, it is conceivable that the concomitant 
administration of phenylbutazone with diphenylhydantoin could potentiate the 
action of diphenylhydantoin. Aggeler ~al (1967) reported that the admin-
istration of phenylbutazone with wa.rfa.rin in normal adult men potentia.ted the 
hypoprothrombinemic action of warfarin. Using equilibrium dialysis, they re-
ported. that the presence of phenylbutazone diminished the association constant,. 
of warfarin for HSA approximatlly tenfold. Potentiation of the hypoprothrom-
bine:n:ic effect by phenylbutazone was attributed to the displacement of war-
fo.rin from serum albu:nin binding sites. Phenylbutazone has been r.eported to 
stimulate hepatic drug-I:Jetabolizing enzymes (Conney ~ &, 1960). However, 
Agseler and associates discounted enzyme induction because the bypoprothrombi-
nemic effect of warfarin was elevated, not reduced. 
When one drug reduces the serum concentration of another, it may indicate 
r that the first drug has stimu1ated the drug-metabolizing enzymes in liver mi-
' ! 
I 
crosomes. However, this phenomenon often requires several days. Eneyme in-
duction causes a decrease in the pharmacological activity of a drug because 
its rate of degradation reduces the concentration of fr.ee drug at the biolog-
ic site of action (Aggeler et ~ 1967). In contra.st, diSPlacement of a drug 
fra:n its serum protein binding sites produces "the apparent paradox of lower 
total blood levels with exaggerated pharmacological reSPonse" (Weiner, 1971). 
The release of a. drug from its binding sites, whether due to competition or 
steric conformation, immediately increases the concentration of free, active 
drug "at the site o:t.' action, but thereafter the drug is also eliminated more 
rapidly from the body" (Sellers and Koch-Weser, 1970). The induction of 
acidosis by the administration of NH4Cl both increased diphenyl.hydantoin a.nti-
MES activity and reduced the concentration of the drug in serum. Thus, it 
would appear that the increase in the pharmacological activity of DPH may be 
attributed to the displacement of the drug from protein binding sites. This 
hypothesis is supported by the !!!. vitro MSA binding data. where unbound DPH 
concentrations were observed to increase as the pH was decreased. 
Weiner (1970) emphasized that both the equilibrium status and kinetics 
of binding competition influence pharmacological activity. He suggested that 
binding competition a.t fi."ed til\Sue structures may not parallel the pattern 
observed in serum. This observation appears to be consistent with the brain-
DPH concentrations, when compared with controls, was paralleled by a slieht 
increase in brain concentration in a.eidetic mice. 
l.~~~~~~~~~~~~~~ 
Although these cha.ng~~--J 
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were not sta.tistica.lly significallt, an obvious trend toward an increase in 
total bra.in DPH concentration was revealed, alld diphenylhyda.ntoin allti-MES 
activity was increased. A closer relationship between bra.in drug levels and 
pharmacological activity ma;y have been established ha.d just the cortex been 
assayed for DPH. Nevertheless, there was an apparent correlation between DPH 
bra.in and serum levels with the anti-MES activity. In general, a.n increase in 
pha.rma.cological activity wa.s attended by an increase in both bra.in and serum 
DPH concentrations. 
As in the case of many investigations, the work accomplished provides the 
answers to some questions, raises others, and opens additional a.venues for 
scientific probing. It wou1d be interesting to canpa.re diphenylhyd.antoin 
binding data, obtained ld th serum albumin ;e'rom patients afflicted with grand 
mal, to resu1ts reported in this work. Furthermore, drug interaction studies 
shou1d be conducted in epileptic patients. DHI serum levels shou1d be deter-
mined in these subjects prior to and during concomitant .administration of 
anticoagulants, analgesics, antibiotics, anesthetics, hypnotics, etc. 
Since disease states can alter the binding characteristics of drugs, 
(McArthur et al, 1971; and Reidenberg et al, 1971), it is possible that the 
binding of DPH to albumin ma;y be influrenced by the disease 'f:or which DPH is 
indicated. '!he importance of in vitro drug binding experiments wou1d be more 
clearly de'f:ined if done usin~ serum proteins from the species in which a.sso-
ciated in vivo exoerirnents a.re conducted. '!his work has indicated the desi-
- -- -
rability of conductin;; DP".d-lii;B.'1-d competition experiments ~ ~ and ~ vitrq, 
using mouse serum albur.iin. Since only the unbou.'1.d form of a drug is con-
sidcred pharmacolosicol.ly active, reports of in vivo drue-serum levels shou1d 
also include the concentration of unbound drug present. 
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CONCLUSIONS 
The results obtained in this work caution against the so1e use Of sermn 
drUg 1evels to determine the bioavailabili ty of a drug. It would appear that 
the concentration of the unbound drug in the serum as well as blood pH and 
serum albumin content would provide a better basis by which to estimate the 
pharmacological activity of a. drug. 
Cone.rd (1971) stated that species differences in drug-plasma protein 
interaction could account for species specific adverse drug reactions. The 
:.!:!! vitro DPH-albumin binding information, together with the ~~results, 
strongly suggest that the interaction between DPH and serum albumin~ con-
tribute to differences in the pha.rma.cological and toxicological activity ob-
served between and within species as well as within individuals. At the anti• 
MES protective dose 100 in mice, the DPH serum concentration was approximately 
14 mcg./ml. The ~vitro binding experiments, in which the MSA retentate con-
tained approximately 17 mcg. /ml., estimate that approximately 95% of the ~ 
vivo serum concentration appeared to be bound by albtunin. In contrast, the 
therapeutic concentration of DPH in human serum is reported to be about 
15 mcg./ml., and in vitro experiments indicate that approximately 8~ of .the 
drug could be bound to HSA. Theoretically, due to the greater capacity of MSA 
to bind DPH, it would require a comparatively larger dose to ca.use death in 
mice as corn.pa.red to man. As an example, Laubscher (1966) ascribed the death 
of a 4-1/2 year old girl to the oral ingestion of 2 g. DPH. Unfortunately, 
l . ' 
:i the weight of the victim was not reported. However, if her weight is esti-
' j mated at 20 Kg., then a dose of 100 mr:,./Kg. DPH was required to cause death. 
! ! F"lnk e.nd Swinyard (1959) reported that the oral LD50 for DPH was 490 mg./IO:;. 
! ! in nice. Wey (1946) reported an intra.peritoneal LD50 of 200 mg./Kg. in mice. 
Th.us, diphenylhyda.ntoin appears to be a.t least twice as toxic in ma.n·as com.-
pared to mice. 
It is the consensus in the great majority of the references cited pre-
viously that drugs bound to serum proteins a.re inactive. Even though a 
larger dose of drug might be required to stimulate a. response in one species 
a.s ccmpa.red to another, it would appear that the 81Uount of unbound drug pres-
ent would provide a. better indicator of drug potency. The a.ffini ty (K) of 
the primary group of binding sites on HSA was approximately twice that of 
MSA; the binding site availability was fifteen to twenty times greater on MSA. 
The a.ffinity·of the secondary group of binding sites for DPH was approximate-
ly 65% greater in MSA than for HSA. · Furthermore, as the moles of drug bound 
per mole of albumin (r) increased, the unbound DPH :fraction available for 
activity in HSA solutions was approximately twice that found in mice. There-
fore, concentration of free drug available for pha.rma.cologica.l action at the 
site of activity should be greater in the human. 
The in vitro and in vivo results presented in this work suggest that a. 
species requiring a. larger drug dosage to ca.use a response may not only be as 
sensitive, but possibly more sensitive than a. species requiring less drug. 
If the drug-serum protein interaction is greater, a.nd the pharmacological 
response equivalent in the latter, less drug would be availahle to produce 
the response. Thus, the organism's sensitivity to the drug could be greater. 
The present work shows that the pharmacological response to DPH is close-
' ly related to albun'.in concentr<ttion, pH, and drut; concentration. Changes in 
these parameters were associated with only s:nn.11 adjustments in the percent-
a.:;e of bound DPH, but were acco:npMied by signi:ficnnt alterations in the un-
bound, active ~ concentration. In vitro druG interaction experiments 
-ll.1-
indicate that binding studies can provide evidence against the assumption tha.t 
the potentiation of a. response may be due to drug displacement fran serum pro-
tein binding sites, and suggest that the increase may be attributed to enzyme 
induction. On the other hand, drug serum protein binding studies ca.n a.lso 
suggest that the potentia.ted activity may be the consequence of drug binding 
site release. 
In conclusion, it is the opinion of this author that !n. vitro drug-
protein binding studies provide a va.lua.ble tool by which to evaluate the 
pharmacological and toxicological action of a. drug in disease states and in 
the stuey of drug interaction. '.!his is especia.lly true in cases where drugs 
a.re highly bound, such a.s diphenylhyda.ntoin. 
_________________________________ ,! 
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CHAPTER.VI 
SUMMARY 
1. Diphenylhydantoin wa.s demonstrated to be highly bound by both human 
sen<m albumin (HSA) and mouse serum albumin (MSA). A total number of 7-8 
binding sites per molecu1e of both HSA and MSA wa.s estimated for diphenylhy~ 
Two groups of sites were determined on both species of albumin 
a primary group with high affinity and a secondary group with much less a.f-
2. Major differences were revealed in the binding of DPH by the two 
types of albumin. HSA wa.s less effective than MSA in the binding of diphenyl-
hydantoin. At concentrations in the albumin retentate corresponding to serum 
values reported as therapeutic in humans, MSA bound approximately 96% of the 
DPH present, and HSA 83%. The secondary group of binding sites on HSA appear 
to bind most of the DPH present, while the primary group of sites were domi-
nant on MSA. The association constant for the primary group of sites on HSA 
was approxilllatelytwice that for MSA, whereas the reverse held true for the 
secondary group of sites. The lysine-}- amino and a.rginine-guanid.o groups 
were postulated as being the prototropic sites on albumin responsible for 
binding DPH. 
3. At a given concentration of DPH in a 4% albumin solution, the con-
centration of free drug increased as the pH was reduced, while the fraction 
of drug bound per mole also diminished. However, the increment in unbound 
' DPH as a function of pH was markedly greater with MSA as compared to HSA. 
4. At a. given pH a.'1d albumin concentration, the fraction of drug bound 
! dir.J.inished while the moles of drug bound per mole of albumin (r) rose as the 
L ·-~·-··--· -~--~~------·----·-*------
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concentration of DPH was increased. The increases in r in this and the a.lbu-
min concentration experiments suggested that the presence of the drug may 
alteration in the steric conf'iguration of the albumin mol.eCUJ.e. 
5. In ligand competition experiments, phenobarbital., trimethadione and 
warfarin at concentrations in the HSA retentate corresponding to serum vaJ.ues 
in the therapeutic range failed to displ.ace DPH from binding sites. In con-
trast, phenylbutazone rea.dil.y displ.a.ced DPH from HSA binding sites. As the 
concentrations of phenyl.butazone were increased, the concentrations of free 
DPH were also el.evated. 
6. The antagonism of maximal el.ectroshock seizures (MES} in mice by DPH 
was potentiated in acidotic mice as measured by a shift in the PD50. This 
effect wa.s attributed to the displacement of DPH from binding sites by the · 
acidotic condition a.nd/or binding site competition with Nli4Cl• No change in 
DPH effect wa.s observed during NaJIC03 induced alka.l.osis. 
7. A positive relationship was demonstrated between a.n increase in serum 
a.nd bra.in DPH levels and a.n increase in DPH anti-MES activity in mice. 
8. Alterations in the pha.rma.col.ogica.l. esponse to DPH due to the effects 
of disease, drug concentration, pH, and albumin concentration were indirectl.y 
and directly related, both through this work and that of others, to the dis-
placement of DPH from serum protein (albumin} binding sites. ~~dis-
placement from binding sites produced an increase in free DPH and, consequent-
ly, an increase in activity. 
9. The results from E:, vit\.o binding site experiments both in this work 
and in the literature were indirectly related to results observed~~· 
i 
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CHAPrER VII 
APPENDIX 
Letter to P11ysicians Concerning PanwarfinR (Abbott) 
De.ta published by Sellers and Koch-Weser (1970) indicated that clinical 
enhancement of coumarin activity in the presence of chloral hydrate was pro-
bably due to the displacement of the coumarin from binding sites. In view of 
this information, Dr. Garnham, Vice President, Medical Affairs, of Abbott 
Laboratories, sent an open letter to physicians concerning Panwarfin therapy. 
The full text of the letter is as follows: 
"Dear Doctor: 
As manufacturers of PanwarfinR (sodium warfarin), we are writing 
to you to bring to your attention a possible problem with concomitant 
use of coumarin anticoagulants a..."ld chloral hydrate. This information ±s 
of particular importance because it is diametrically opposite to that 
previously believed. 
Following a publication by Cucinell .=! ,!!± in 1966, it had been 
considered that use of chloral hydrate with coumarin anticoagulants 
could lead to inhibition of the anticoagulant effect. It was ob,served 
that, like certain barbiturates, chloral hydrate shortened the serum 
half-life of bishydroxycoumarin. A similar action, enzyme induction, 
was postulated as the cause of this reduction of the half-life. New 
evidence suc8ests that this may not be so. 
' Very re~ently, Sellers and Koch-Weser2 published an article show-
ing enhance:nent of the hypoprothror.ibinemic effect of warfarin sodium. 
Increases of as much as 40 to 80 percent in this.effectwere noted 
! 
1 L,, ____ _ 
---------------·-........ _.._.. ..... __ ~ 
:following concomitant administration o:f so6f'uii:~;:;:farin ~d 1 gin.· of 
cb1oraJ. hydrate daily for one week. The authors $tudied 237 ho$J?itaJ.ized 
patients receiving both drugs and observed only potentiation of warfarin-
induced hypoprothrombinemia, and !!2. inhibition. 
This recent article suggests that hte mechanism involved is the 
displacement of warfarin by a metabolite of cb1oraJ. hydrate (tricb1or-
acetic acid) from serum aJ.bumin-binding sites. I:f cb1oraJ. hydrate is 
added to the therapy o:f a patient maintained on sodium warfarin, the 
authors recomment athat a reduction in anticoagulant requirement should 
be anticipated to avoid excessive hypoprothrombinemia with risk of 
bleeding. On the other hand, discontinuation of cb1oraJ. hydrate therapy 
in patients of warfrain may make it. necessary to increase warfarin 
dosage to maintain adequate anticoagulation. 
Every e:ffort is made to assure that our product literature reflects 
current medicaJ. knowledge, and our package insert for Panwarfin has been 
changed to indicate the above findings regarding concomitant therapy 
with sodium warfarin and cb1oraJ. hydrate. 
While this new in:formation applies only to cb1oraJ. hydrate, the 
scope and importance of the drug interaction problem becomes daily more 
evident. The controlled study of drug interactions is a relatively new 
field, and only a portion of the possible combinations have yet been 
examined. 
It is, therefore, likel(r that additional knowledge in this area 
will continue to accrue. THE IMPORTAUCE OF CAREFUL MONITORING OF 
PROTHRO:.IBilI TD!E WHS;JEVER ANY DRUG . IS ADDED TO OR WTIHDRAWN FROM THE 
REGIMEN OF A PATIENT ON ANY OF THE COUNARIN ANTICOAGULANTS CANNOT BE 
l ···-··~-·--.,-.. ~--·---· --------:J.16.._---~---.-.· ------ ----·-~ 
OVER-EMPHASIZED. II 
(Signed} John G. Garnham 
~ .......... ...........,. ..... ____ . ____ ··- ---·-----------.,.._.-~.,~-_J 
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Determination of Diphenylhyd.antoin: Drug Preparation (Conard, 1969); Isotope 
Dilution Technigue ( Zaroslinski and associates, 1969, 1971} · 
Diphenylhydantoin (DPH) concentrations were determined using the radio-
isotope dilution technique. DPH is considered only sparingly soluble in dis-
tilled water; sparingly soluble was defined as 30-100 parts of solvent to l 
part of solute or 10-30 mg./m1. (Sunshine, 1969}. However, it was determined 
that the solubility of the drug is drastically reduced in buffer solutions of 
pH 7.0 - 7.6. Conard (1970} attempted to characterize the binding of diphen"'. 
ylhydantoin to rat and human werum while Rudman (1971} tried to determine DPH 
binding sites on both human and bovine serum albumin. However, both investi-
gators vere thwarted by the insolubility of' the compoWld at experimental con-
ditions employed. Conard partially solved this problem by solubilizing and 
concentrating the drug in O.Ol N NaOH. Then he added an aliquot of the con-
centrate to the buffer diffUsate prior to dialysis •. In the present study, it 
was determined that Sorensen's buffer solution (pH 7.0 - 7.6} would hold ap-
proximately 0.07 mg./ml. DPH which had been previously solubilized in 0.01 N 
NaOH, while a 4% buffered albumin solution would retain DPH solubility up to 
o.6 mg./m1. Thus, in these investigations, the solubility problem was suit-
ably solved by dissolving DPH in 0.01 N NaOH and adding a 0.1 m1. aliquot of 
the DHi concentrate to a serum albumin chamber containing 4.6 m1. ot a 
4.174% albumin solution. Then 0.1 ml. diphenylhydantoin-4-c14 (approximately 
101 000 cpm) was added to the albumin chamber. In total, the albumin reten-
tate chamber contained 4.8 ml.,fo an albumin solution consisting of 4% al-
; bur:Un and the appropriate concentration of radioisotope labeled DPH. Ex-
periments were conducted to assure that neither the drug nor the NaOH ve-
hicle altered the pH of the solutions or the counts. 
l· ... 
- •.,,., _________________________________ _.. 
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Samples were handled as indicated on page 46 and quenching corrections 
were made following the ratio of channels ratio method described by Zaro-
slinski and Mais (1969), Zaroslinski et al (1971) and Oester et al (1971). 
-- ~.-
Preliminary experiments revealed that the counting efficiency fo the instru-
+ . 
ment was approximately 100- 'i!fo when the labeled sample in the bUffer alone 
was counted. Only a slight decrease in efficiency was observed with the 
ad.di tion of albumin. .· With the 4% albumin present, the counting efficiency 
dropped to approximately 98'!~. Therefore, counts taken from the bUffer 
retentate samples were assumed to be 100%. Both bUffer diffusate and al-
bumin retentate samples were counted using two different windows to provide 
for the determination of a channels ratio value for each sample. A quench 
correction factor was obtained by dividing bUffer diffusate channels ratio 
by its associated albumin retentate channels ratio (B/A}. · The albumin 
counts from the primary window were then corrected for quenching by multi-
plying those counts by the B/A ratio factor. When this method was compared 
to the quench curve technique, corrected values were comparable. 
By following the techniques described, the percentage of drug bound 
deviated by less than o.6% between duplicate dialysis experiments. There-
fore, two experiments per point were considered sUfficient. 
f _________ _ 
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Pl'otein Determination 
The method described by Gornal.l ~ !! (1949) is based on the formation 
of a violet color when a strongly alkaline solution of copper sulfate reacts 
with proteins or polypeptides having a peptide or amide linkages. 
Reagent: Gornal.l ~ ,!! biuret reagent contains 6.o gm. potassium tar-
trate {NaKC4lf406.4~2o )and 1. 5 gm. cupric sulfate ( CuS04. 5Hi)) dissolved in 
approximately 500 ml. of distilled water to which has been added 300 ml. of 
10~ NaOH. This solution was then gs. to 1 liter with distilled water. 
A 0.1 ml. aliquot of the matching protein and buffer retentate solutions 
was pipetted into separate test tubes using a Hamilton microliter syringe. 
to each of the test tubes was added 0.9 ml. of the appropriate Sorensen's 
buffer using a Mohr measuring pipette. To a separate test tube was added 1 
ml. Sorenson's buffer (reagent blank). Four ml. of the Gornall reagent was 
pipetted into each tube and the mixture allowed to stand for 30 minutes at 
room temperature. The optical densities of the solution·were dete:nnined in 
a Beckman DU-2 using one cm. cells at 540 mu. 
Both human serum albumin and mouse fraction V serum albumin standards 
were used as controls. Various concentrations were employed to plot stan-
dard curves from which protein concentrations were determined. This assay 
was accurate enough to detect protein changes of 0.1 percent. 
L."-------~----~--· -----------.i 
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Detennination of Sodium 
Sodium concentrations -were measured using flame photometry. Inflame 
photometry, the radiation {optical density) of a known amount of a solution 
of sodium is measured and compared to the radiation of a comparable solution 
containing an unknown amount of sodium under identical conditions. All sam~ 
plea were diluted freshly with triple distilled water. 
Blank, albumin retentate, and buffer diffUsate samples were analyzed 
for sodium. ion content using a dilution ratio of 1:200 as follows: 
I. Preparation o:f' Stock Reagents 
a) Reagent 1: :five ml. of 100~ Sterox SE was pipetted into a 500 
ml. volumetric :flask which contained approximately 490 ml. 
distilled water. Then the flask was filled to the mark with 
distilled water. 
b) Reagent 2: fifty ml. of Sodium Flame Photometry Standard "A" 
was measured into a 500 ml. volumetric flask and the flask filled 
to volume. 
c) Reagent 3: (0.75 mEq/l. sodium and o.o~ Sterox SE): fifteen 
ml. of Reagent 2 and 10 ml. of Reagent 1 were pipetted into a 
500ml. volumetric flask and the flask filled to VOlUIQe. 
d) Reagent 4 (0.5 mEq/l. sodium and o.o~ Sterox SE): tM;lll· .of 
Reagents 1 and 2 were pipetted into a 500 ml. volume~~~ flask 
and the flask filled to volu.~e. 
e) Re17gent 5 ( 0.02~ aterox SE, reagent blank): ten ml. o:f' Reagent 
1 was pipetted into a 500 ml. volumetric flask ana.· the flask 
filled to volume. 
Note: all of these stock reagents were stored in polyet-leme bottles. ~~------.. J 
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II. Sample Preparation and Analysis 
a) A sample aliquot of 0.25 ml. was pipetted into a 50 ml. volu-
metric flask containing 45 ml. distilled water, using an Ost-
wold-Folen pipette. 
b) One ml. of Reagent l was added to each flask; then the flask 
was filled to volume. 
c) After the solutions had been well mixed, the pre-labeled 10 
ml. pyrex beakers were filled approximately 4/5 full with the 
appropriate solution. 
d) Separately labeled beakers were filled vi.th Reagents 3, 4, and 
e) All samples were atomized and the percent transmittance re-
corded. Reagent 5 served as the reagent blank and also to 
flush the atomizing device clean between eXPerimental samples. 
A 10 - 15 second flushing time was utilized. 
f) The percent transmittance values recorded vi th Reagent 3 and 
4, representing 150 and 100 niEq./l. sodiwn respectively, were 
used for preparing calibration graphs. 
g) The ratio of the amount of sodium in the albwnin retentate 
solution to the sodium content of its sister buffer solution 
was employed to correct DPH dialysis values for Donnan 
effect. 
r 
I'' 
I 
,, 
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Estimation of Protein Binding Sites and Association Constants-
Method of Karush (1950) and Scatchard et al (1957) 
The mathematical analysis of binding data has been thoroughly discussed 
by Scatchard (1949), Sca.tchard et al (1950, 1957), Ka.rush and Sonenberg 
(1949), Ka.rush (1950), Edsall and Wyman (1958), Goodman (1958), Keen (1966), 
and Rudman et al (1971) . Browne (1969) summarized the manner in which these 
investigators estimated the number of binding sites per molecule of albumin 
and their association constants with regard to l or 2 classes of binding 
sites as follows: 
l. The moles of drug bound per mole of albumin (r) is determined for 
several concentrations of the drug. 
2. Then (r) is related to the molar concentration of the free drug 
present (c) by preparing a plot of r/c vs r values. 
3. The curve resulting :from the r/c vs. r relationship is extrapolated 
to the ordinate and the abscissa.. The authors state that, the values at the 
intercept points on the ordinate and abscissa wqual nK and n respectively. 
"K" is equal to the association constant and "n" equals the number of bind-
ing sites. 
According to these authors, a plot of the r/c vs. r values produces a 
straight line when a single, homogeneous group of sites is responsible for 
drug binding. Scatchard points out that the relationship between the con-
centrations of bound and free drug is expressed by the formula: 
(1) <t:/c = nK - nr 
Should the r/c vs. r plot produce a curved line, the deviation from a straight 
line may be due to electrostatic interaction. Electrostatic interaction is 
attributed to the repulsion of approaching drug ions by those already bound. 
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An electrostatic correction factor mizy be applied by plotting r/c (f) vs. r, 
-
where f equals e2w(Zp+r). "e" is the natural log, "w" the Debye-Huckie para-
meter, and Zp is the net charge on the protein. The relationship between the 
concentrations of bound and free drugs, corrected for Donnan effect and 
solute space, are represented by the formula (Keen, 1966b): 
(2) r/c (f) = nK - rK 
If a curved plot persists after r/c correction for electrostatic inter-
action, heterogeneity of binding sites is assumed. The experimental plot is 
extrapolated to graphically estimate the total number of binding sites, the 
number of binding site groups, and their affinity for the a.gent being studied. 
"Assuming that there are n binding sites of two types, n1 and °2 with associa-
tion constants K1 and ~' and A is the l~ting value of r/c as c approaches 
zero", the equation for the relationship between free and bound drug concent-
rations is : 
(3) r/c = nl Kl + nl ~ 
1 + K1c l. + ~c 
where n = n1 + n2, and line r/c = n1K1 + n~2 = A (Karush, 1950; Goldbaum and 
Smith, 1954). The association constant (K) for each cl.ass of sites is deter-
mined by dividing the cl.ass nK value by its n value. 
T'ne graphical.ly determined n and K values are substituted into the appro-
priate equation to sol.ve for r/c. The calculated r/c ratio vs. r values are 
pl.otted. The pl.ot should procuce a curve similar to that originally drawn 
, and extrapolated (Keen ,1966b). 
' Should the u·se of equation (3) fail to resolve the curve into 2 separate 
! 
; components, then it is probabl.e that more than two cl.asses .of binding sites 
' 
· exist. In 1957, Scatchard a...'1d associates foresaw this inevitability and math-
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ematicaJJ.y caJ.culated a formula to determine multiple binding site classes. 
When the curve is "concave upwards" or as we have found is more arc shaped 
than "L" shaped, multiple binding sites (>2) exist. The basic equation in 
the Scatchard anaJ.ysis is : 
(4) g- -E niKic r = iri - i ---
1 + ~c 
The curve resulting from the Scatchard type plot for the diphenylhydan-
toin binding site data was resolved by Il:M 360 computer for equation {3) 
employing the Non-linear Least Squares technique. The program. utilized was 
obtained by Conard (1971) from the Vogelback Computing Center, Northwestern 
University, Library Number NU CC 260,. Subroutine NLSQ. This computer program. 
originating from work published by Hartley (1961), Marquardt (1963), and 
Draper (1966) was refined and updated by Stein and Cohen (1971). The general 
description of the program is described by the Vogelback Computing Center a.a 
follows: 
"The subroutine finds the constants of the equation, 
y = f(X, b) = f(x1x2, ••• , Xp ; b1 , b 2 , ••• , bm) (1) 
Where X is the matrix of independent variables, y is the 
vector of dependent variables and b is the vector of coefficients to'be 
estimated. 
(? XU Xi2 ?p) must be given. • . . . . . 
Yn "r.J. Xn2 ~p 
b = Ci11' 
I (2) The coefficients, • • • • • ,. bm) ' 
are computed by minimizing the least squares :function, 
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n 
s = C [ Yi - f(Xj_, b) ) 2 
i=l 
Computational Procedure 
(3) 
The classical least-squares problem (3) is solved by a modified Gauss 
Newton method using the Marquardt sea.ling factor I. Let h be the 
index of the h-th observation and expand f(Xh ; b) in a first order 
Tablor series about b , an initial estimate of b, 
0 , 
f(Xh ; b) = f(Xh ; b0 ) +f~f(Xh ; bo)) (b - b0 ) l b h = l, ••• ,n 
writing z = (f(x1 ; b) , ••• , f(Xh; b)) 
, 
, 
Z0 = (f(X1 ; b0 ) , ••• , f(Xn_ ; b0 )) 
a f(X1 ; b0 ) ••• ~f(X1 ; b0 ) 
bl bp 
Do = 
. 
. 
~ f (X bo) 4f(X . bo) n . , n ' 
C> bl ()bp 
we have, in matrix form 
Z = Z + D (b - b ) 0 0 0 
What the program does in the first iteration is to find the 
difference d = (b - b ) such that, 0 0 
I (y - Z0 ) (y - Z0 ) = s(b0 ) 
is minimum. Substituting (6) into (3) and minimizing with 
respect to do yields a system of normal equations 
, -1 , do = (Do Do) Do (y - zo) 
' a new solution b1 is found such that b1 = b0 + do 
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(4) 
(5) 
(6) 
(7) 
(8) 
So that, in general, we have at the (K + 1)-th iteration 
bK+l = bK = dK 
~ = (D~ n:. (y - Zic) 
The iteration process is terminated in any one of the following 
wa.ys. 
1. The number of iterations exceeds a pre-specified limit. 
2. The absolute relative change in the sum of squares from 
any two successive iterations is less than or equal to 
a prescribed constant i.e., 
8K+1 - 8K 
SK 
< £ 
3. The absolute relative change in any one of the parameters 
in any two successive iterations is less than or equal to 
a prescribed constant i.e., 
<£ for all i 
Marquardt's modification to the Gauss Newton method represents 
a compromise between linearization (via Taylor series} and the 
steepest descent method and accelerates convergence, the com-
putation of dK is given by 
dK = (D~ DK - I)-l n; (y - Zic) 
where Ai~ Marquardt' s s~aling factor 
Because of attenuation in the s(b) contours, we may get 
(9) 
(10) 
(11) 
(12) 
(13) 
SK+l> SKi in which case A is multiplied by an adjustment factorC(. 
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Usage 
Cal.ling Sequence 
CALL NLSQ (FUN, FGRAD,X,Y.F.B.EPS,GAA,V,WORlU,WORK2,NOB NP,MIT,IDIMX, 
IER) where, 
FUN - Name of user supplied subrou~ine that computes the vaJ.ue of 
the f'unction, VAL, for val.ues of the coefficients b and 
independent variables X. The form of the subroutine is, 
SUBROUTINE FUN (B,S,VAL) 
DIMENSION B (1), X (1) 
I 
. 
roMPUTE VAL = f[b(l), ••• ,b(NP), X(l), ••• , X(NX)] 
FUN must be declared in an external statement in the caJ.ling 
program. 
FGRAD -Name of user supplied subroutine that computes the gradient 
values. 'The form is, 
SUBROUTnlE FGRAD (B X,GRAD) 
J)Il·!ENSION B(l), X(l), GRAD(l) 
. 
~ = f~b (1), ••• , b{NP), X{l), ••• X{NX) 
() b{!) 
for I from 1 to NP. FGRAD must be declared in an exter-
nal statement in the cal.ling program. 
X - 2 dimensional arra:y of row size NX ( the number of independ-
ent variables ) and column sixe NOB ( the number of obser-
vations) speci:t'ying the values of the independent variables. 
The variables x(.r;r) contains the value of j-th variable 
on the i-th observations. 
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Y - 1 dimensional array of size NOB that contains the observed 
dependent variable. 
F - 1 dimensional array of size NOB that contains the final 
fUnction values computed at each set of independent var-
iables. 
B - 1 dimensional array of size NP that contains the resultant 
constants. Initial estimates of B must be specified prior 
to the call. 
EPS - Specifies the desired accuracy ( 8 ) . Suggested value = 
lo-8. 
GAA - Marquardt scaling factor { ~). For a detailed explanation 
of this variable see reference 1. If the choice must be 
made arbitararily the recommended value is 2.0. 
v Adjusted factor. Again see reference 1 for a detailed 
explanation. If the choice must be made ·arbitrarily the 
recommended value is 1.5. 
W'ORKl - Work area of size 2•(NP2). It is used internally as a 
storage area. It may be used in the calling program for 
other purposes, but its contents will be destroyed when 
NLSQ is called. 
I 
I 
! 
! 
W'ORK2 - Work area of size 4·NP. The same statements about WORKl 
apply. 
N'.>B Integer specifylng the number of observations (n). 
NP - Integer specifying the number of constants to be computed 
! (m). NP must not be greater than l'IOB. 
' 
r I l '----
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MIT - Integer specifying the maximum number of iterations the 
subroutine may perform. 
IDIMX - Integer specifying the row dimension of the array x. It 
must be at least NX (the number of independent variables). 
IER - Error parameter. Upon return this indicates su~cess or 
failure of the computation. 
IER = 1 indicates that convergence was not obtained in 
MIT iterations. 
IER = 2 indicates that NP > NOB and no computation was 
performed. 
IER = 3 indicates that a singular matrix ~TI\ - ~ I 
was encountered and the computation was aborted at 
that point. 
The variables X, Y, b, EPS, GAA, V, NOB, NP, MIT, and IDIMX, all 
must be initialized prior to calling NI.SQ. 
Coding Information 
The statement, 
EXTERNAL FUN, FGRAD 
MUST appear in the calling program. 
Required Subprograms 
FUN and FGRAD 
Common Storage 
None 
Exarnnle 
f 
I f The following program finds the values of b1, b2, and. b3 for any 
'--· ----·---·-----·--· ---------------
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set of observations points. The fUnction is, 
• (14) 
The gradient vector is, 
A program to read the observation points and find the correspond-
ing constants is given below. (TH is equivalent to our B) 
PROGRAM NLSQEXP (INPUT O'l1rPUT) 
Dll·IBNSION x(3,15),Y(l5~,F(l5),TH(3),woRKl(l8),woRK2(12) 
EXTERNAL FUN,FGRAD 
NP = 3 
READ 100, NOB 
100 FORMAT (15) 
READ 101, (TH(J),J=l,NP) 
101 FOR.\1AT (8Fl0.3) 
DO 2 I = l,NOB 
2 RE.AD 101, Y(I),(X(J,I),J+l,3) 
CALL NLSQ (FUN,FGRAD,X,Y,F,TH,EPS,GAA,V,WORKl,WORK2,NOB,NP,MIT,3 
l,IER) 
PRINT 102,IER,(TH(J),J+l,NP) 
102 FORMAT (1X,8HERROR = ,11,llH RESULTS = ,3(Fl0.7,lx)) 
STOP 
END 
SUBROUTil'lE FUN (TH,X{F) 
DIMENSION TH(l) ,X(l) 
F = TH(l) + X(l)/(TH(2)*X(2)+TH(3)*X(3)) 
RETURi"l 
END 
SUBROUTINE FGRAD (lH, X, GI'vID) 
DIMENSION TH(l),X(l),GRAD(l) 
GRAD(l) = l. 
FACTOR= -x(l)/(TH(2)*X(2)+TH(3)*x(3))**2 
GRAD (2) = FACTOR*X(2) 
GRAD(3) = FACTOR*X(3) 
RETURi~ 
END II 
L----------------------------.....1 
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Maximal Electroshock.· Apparatus (Woodbury and Davenport, 1952) 
as Modified by Sittig, R.A. (1961) 
Prior to 1952, the methods for electrically inducing seizures in experi-
mental animals for studying anticonvulsants varied widely, resulting in con-
trasting results between investigators. The instrument origin~ designed 
by Woodbury has become a standard piece of pharmacological equipment because 
it provided controlled types of electrically induced seizures and repro-
ducibility of results. Instrumental modifications were incorporated by 
Sittig to further sophisticate the instrument and to simplify its operation. 
The circuit diagram is illustrated in Figure 15. The parts list for the 
electroshock apparatus is as follows: 
Si Interlock switch on cabinet door 
s2 Master Switch 
s3 Push button to initiate timer; normally connected to timer 
S4 Timer switch 5 pole, single circuit wafer type 
s5 Current range switch, porcelain base, high voltage 
T1 Small replacement type transformer 350-o-350 volts 
T2 Variable autotransformer, 3 ampere capacity 
T3 Plate supply transformer, primary llO volts, secondary 2000 
volts, 400 ma 
C Timer condenser, 5 mfd, 1000 volts 
Ryl Sensitive relay, 10,000 ohm winding 
Ry2. Heavy duty, double l)Ole relay or contactor, llO volt coil 
Adjust to give 25-30 ma through regulator tubes; approximately 
2,000 ohms 10 watts. 
10 K 10 turn precision potentiometer 
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R3 5000 ohm 1 watt resistor 
R4-Ra Wire wound, 100 watt variable resistors with sliding taps. 
Adjust to give desired fUll scale current. The following are 
approximate: 
R4 120,000 ohms 
R5 40,000 ohms 
R6 30,000 ohms 
~ 16,000 ohms 
R8 4,ooo ohms 
Meter (Indicated by circle-enclosed arrow in lower le~ part of dia-
gram). Any meter capable of reading rms a-c volts; scale may be hand-
calibrated to give desired current ranges. 
Any desired additional information may be obtained from the Woodbury 
and Davenport reference. 
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